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ABSTRACT

CD36 is a Class B scavenger receptor expressed on platelets, erythrocyte
precursors,

monocytes,

microvascular

endothelial

cells,

epithelial

cells,

adipocytes, and cardiac and skeletal myocytes. It recognizes multiple ligands
including thrombospondins, oxidized phospholipids and apoptotic cells, and has
been shown to play a role in phagocytosis, angiogenesis and atherosclerosis.
The function of CD36 on platelets is incompletely characterized, but our group
has recently identified CD36 on platelets as a signaling receptor which can
modulate platelet function by binding to ligands such as oxidized LDL.
Endothelial cell (EC) derived microparticles (MP) have been identified in the
circulation of patients with diseases such as diabetes, anti-phospholipid
syndrome and acute coronary syndrome in which patients are prone to arterial
thrombosis, and thus platelet activation and aggregation play a pivotal role.
Because EC MP express phosphatidyl serine (PS) on their surfaces, a potential
CD36 ligand, we hypothesize that MP may bind to platelets via a PS-CD36
interaction and function to transmit an activating signal, thereby promoting a
prothrombotic state.
vi

To test this hypothesis, we first isolated EC-derived MP by stimulating
human umbilical vein EC with TNFα and cyclohexamide according to a
previously published protocol. MP were characterized and quantified by flow
cytometry and shown to express CD105 and PS. Binding of MP to platelets was
detected and quantified by flow cytometry and immunofluorescence microscopy.
Platelet activation was assessed by aggregometry and flow cytometry. Washed
human platelets (CD105 negative) were incubated with EC-derived MP at a ratio
of 1:9 and analyzed by flow cytometry with a fluorescence tagged anti-CD105
dye) positive MP formed rosettes around (Calcein-Green Tagged) platelets. With
both the flow cytometry and microscopy assays, platelet-MP association was
inhibited by addition of anti-CD36 antibody or by using platelets from CD36 null
donors. This inhibition by CD36 antibody was statistically significant (p=0.02).
Furthermore, pretreatment of platelets with other CD36 ligands such as oxLDL
inhibited MP-platelet association by more than 50%. Next we determined the
functional effect of the MP-platelet association.

We observed a significant

increase in the rate and extent of platelet aggregation to low concentrations
(2µM) of ADP and an increase in platelet secretion (measured as surface Pselectin expression) when platelets were incubated with EC-derived MP prior to
addition of agonist. This effect was markedly diminished in platelets from CD36
null donors and also inhibited by pre-incubation with anti CD36 antibody. To test
the MP-platelet interaction in vivo, carotid arteries were injured by FeCl3 in wild
type and CD36 knock out mice. The thrombosed arteries were sectioned and
immunostained with an endothelial cell specific antibody to CD105 (red) and a
vii

platelet specific antibody to CD61 (green). We reasoned that CD105 staining of
thrombi would reflect incorporation of EC-derived MP into the thrombi.

We

observed significantly more CD105 staining within the thrombi from wild type
mice compared to CD36 null mice,
We thus propose a model where CD36 ligands presented to platelets
renders them “hyperactive” predisposing patients to pathological thrombosis. It is
also possible that CD36 ligands such as EMPs, generated during an acute
thrombotic event, could increase the thrombotic response in a CD36 dependent
manner by signaling platelets in a positive feedback loop.
CD36 expression levels have been reported to vary significantly among
normal human subjects. We thus hypothesized that levels of expression in an
individual donor would correlate with platelet reactivity in response to CD36
ligands.

We developed a quantitative flow cytometric technique to measure

CD36 surface expression on platelets and studied 32 normal healthy volunteers.
We found that expression levels were highly variable ranging from as low as less
than 2000 molecules per platelet to more than 14000 molecules per platelet. We
then replicated this study in a larger population (567) of subjects who came for
screening at the Cleveland Clinic Cardiac Catheterization lab.

To assess

whether this variability of CD36 expression had a functional effect, donors were
selected from high, medium and low expressing groups, and their platelet
reactivity to oxLDL was analyzed by flow cytometric techniques. Results showed
a very good correlation of platelet activation by oxidized LDL with levels of CD36
expression.
viii

Having shown that CD36 expression levels varied among individuals but
was consistent over time in any single donor we hypothesized that a component
of the variance was heritable. We identified 10 tagged SNPs in the CD36 gene
from the International HapMap consortium website. DNA from the 550 subjects
described above were then genotyped for the tagged SNPs and 3 SNPs were
found to be significantly associated with expression level (rs3211864, p value
0.023, OR=0.55; rs3211932, p value=0.02, OR=0.617 and rs1537593, p
value=0.03, OR=1.067). For all of these SNPs the minor allele was associated
with lower levels of CD36 expression. These data suggest that the variability of
CD36 expression on platelets is at least in part genetically determined and
together this phenotype-genotype can affect platelet function.
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CHAPTER I
INTRODUCTION
PLATELETS

The mammalian hemostatic system is a defense mechanism whose
function is to preserve the integrity of the high-pressure circulatory system. An
intact vessel wall lined by endothelial cells maintains an inert surface that helps
to traffic blood flow without interaction of the blood cell components
(erythrocytes, leukocytes and platelets), or the soluble plasma proteins required
for blood coagulation with the endothelium. Platelets are anucleated cells that
originate from their precursors, the megakaryocytes and “circulate in the blood
surveying the integrity of the vascular system” (Ruggeri, 2000). When the lining
of the vessel wall is disrupted, platelets are engaged by the body’s defense
mechanism on the exposed subendothelium to form a clot and thereby seal the
leak in the blood vessel. However platelets cannot distinguish between traumatic
wounds in the vessel lining and other potentially pathogenic “lesions” on the
vessel wall and can form thrombi at sites of ruptured atherosclerotic plaque. The
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otherwise beneficial defense mechanism, now becomes an important cause of
heart attacks, strokes and peripheral vascular diseases.

Platelet adhesion:
The first step in hemostasis is platelet adhesion which is highlighted by the
platelet-subendothelial matrix interaction. The constituents of the exposed sub
endothelium including collagen, von Willebrand factor (vWF), fibronectin, laminin
and thrombospondin mediate this interaction. Platelets bind to vWF via platelet
membrane glycoproteins GP1b-IX-V complex (Fig 1). The history of this
discovery dates back to 1948 when Bernard and Soulier reported two children of
consanguineous parents with a mucocutaneous bleeding disorder, giant sized
platelets and thrombocytopenia (Lopez et al., 1998). Later, based on the
pioneering studies by Nurden and Caen that identified a defect in platelet GP1b
as a cause of Bernard Soulier syndrome (Caen et al., 1976; Nurden and Caen,
1975), many others have provided important information about the interactions
between platelet glycoprotein receptors GP1b and GPIIbIIIa (α2bβ3) with vWF.
vWF-GP1b interaction can transmit signals that initiate α2bβ3 activation (De Marco
et al., 1985; Kasirer-Friede et al., 2004). This receptor complex allows firm
anchoring of platelet monolayer to the vessel wall. Also, it has been shown that in
conditions of high shear as seen in arterioles or larger arteries, it is vWF that
mediates stable surface adhesion (Savage et al., 1996). The effect of shear may
explain both the very large size and the multimeric structure of vWF. Collagen

2

also contributes to platelet adhesion by binding to α2β1 and GPVI (Clemetson
and Clemetson, 2001).
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Fig 1. Schematic diagram showing the classical platelet adhesion,
activation and aggregation. Adhesion involves interaction of the specific
platelet receptors with collagen and vWF. Adhesion leads to platelet shape
change and release of granules (ADP, TxA2) and activation. There are specific
G-protein coupled receptors for ADP (P2Y12 and P2Y1) and TxA2. Finally,
platelet aggregation is a result of the cross-linking of activated α2bβ3 molecules
expressed on two different platelets by fibrinogen or vWF (Adapted from
“Antiplatelet drugs” G.J. Hankey and J.W. Eikelboom, The Medical Journal of
Australia)
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Platelet activation: shape change:
The adhered platelets undergo shape change and activation. Shape
change is typically described as a change from the discoid form to a spherical
form. The platelet granules then retreat towards the center and finger like
filopods are extended from the surface leading to spreading of the platelets
(Hartwig, 2006). Reorganization of the actin cytoskeleton and intracellular
signaling drive the alterations in the platelet morphology (Maxwell et al., 2006).
Shape change is very rapid, beginning within seconds and completed within a
minute after exposure to agonists.

Platelet activation: secretion:
The initial platelet “plug” now undergoes “extension” by recruitment of
more platelets (Fig 3). Recruitment is mediated by the local accumulation of
molecules that are secreted or released from activated platelets such as
Adenosine diphosphate (ADP) and TxA2 (Thromboxane A2). A large number of
granule contents (from alpha and dense granules) are released from activated
platelets and these can significantly modify platelet activation. The dense
granules of platelets contain important agonists like ADP and serotonin. “ADP is
predicted to be the prominent amplifier of initial platelet aggregation” (Gachet,
2001). It interacts with specific extracellular membrane receptors to induce
intracellular signaling. When platelets are activated, diacylglycerol (DAG) and
inositol triphosphate (IP3) cause release of calcium from the dense tubular
system. Intracellular calcium levels increase and this causes exocytosis of
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platelet granules. There are two classes of receptors for ADP, P2Y1 and P2Y12
which belong to the seven transmembrane receptor family (Dorsam and
Kunapuli, 2004; Fabre et al., 1999) and P2X1 which belongs to the ADP/ATP
driven calcium channel family of purinergic receptors (Sun et al., 1998). ADP
interacts with P2Y1 to mobilize calcium and shape change and “transient
aggregation” (Fig 1) (Fabre, 1999 #320). P2Y12 receptor is believed to potentiate
platelet secretion and to be involved in “sustained irreversible platelet
aggregation” (Dorsam and Kunapuli, 2004).
Serotonin is another bioactive substance released from the dense
granules. It is a vasoconstrictor and by binding to G-protein coupled receptor
5HT2A, it exerts its action locally (Baumgartner and Born, 1968). Interestingly,
Dale et al described a new concept in platelet biology called the “coat platelets.”
These are platelets activated by thrombin and collagen that bind serotonin to
retain certain procoagulant protein such as alpha granule protein factor V,
fibrinogen and thrombospondin on their surface (Dale et al., 2002).
Platelet alpha granules are the most abundant secretory granules in
platelets (Sixma et al., 1989) and release a large number of adhesive proteins
(vWF, thrombospondin, fibronectin); mitogenic factors (PDGF, TGFβ, VEGF);
coagulation factors (factors V, VII, XI, XIII). Some glycoproteins such as
Pselectin (CD62P) is localized to the surface of the alpha granule membrane and
are trafficked during platelet secretion to be exposed on the surface of the
activated platelet. In recent years a number of important functions have been
attributed to P selectin and these include platelet binding to neutrophils and
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monocytes (Singbartl et al., 2001) or leukocyte rolling on platelets (Furie et al.,
2001). Patients with alpha storage pool disorder have diminished or absent alpha
granules and a variable bleeding diathesis (Weiss et al., 1979).
Platelets also synthesize thromboxane A2 (TxA2) which is produced from
arachidonic acid in platelets. Arachidonate is derived from phospholipids by the
enzyme phospholipase C, it is converted to TxA2 by the cycloxygenase pathway,
of which prostaglandin H2 (PGH2) is an important intermediate (Fig 1). Once
formed, TxA2 can diffuse across the plasma membrane and like ADP can
activate and recruit other platelets. TxA2 receptors on platelets are physically
associated with G protein family (Fig 1). TxA2 and ADP together with the other
agonists produced at the site of vascular damage (thrombin) modulate platelet
adhesion and activation.

Platelet-coagulation protein interactions:
Another important step in platelet activation is localization of subsequent
procoagulant events to the injury site. Activation of platelets leads to assembly of
a prothrombinase complex on their surface (Fig 2). A very important mechanism
for formation of the prothrombinase complex on the surface of the platelets is
reversal of membrane asymmetry. Once there is rise in intracellular calcium
levels in the ADP or thrombin activated platelet, an enzyme called the
phospholipid scramblase (Williamson et al., 1992; Zwaal et al., 1993) causes
rapid flip-flop of all the major internal phospholipids such as phosphatidylserine
(PS) and phosphatidylethnolamine to exteriorize (Fig 2). This is vital for the
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assembly of the prothrombinase complex on the platelet surface (Zwaal, 1978).
The prothrombinase complex is capable of converting large amounts of
prothrombin into thrombin to form a consolidate platelet-fibrin thrombus (Fig 2).
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thrombin
Xa
PS
thrombin
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activated platelet
PS PS
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Thrombin
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Fig 2. Platelets and formation of prothrombinase complex: The activated
platelet expresses PS (phosphatidylserine) on their surface due to reversal of
membrane asymmetry. This allows activation of several blood coagulation factors
on the platelet surface. Activated Factor Xa binds to Factor V on the platelet
surface to form the prothrombinase complex. This prothrombinase complex is
capable of converting prothrombin into thrombin which in turn can clot fibrinogen.
Tissue factor (TF) is expressed on the surrounding extravascular cells and TF
can generate minute quantities of thrombin which can initiate the coagulation
pathway by activating factor XI on platelets. (adapted and modified from Current
concepts of hemostasis, Richard B. Weiskopf, Anaesthesiology 2004; 100:71130).
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Platelet aggregation:
The aggregation of platelets results in the accumulation of platelets into a
hemostatic plug. Platelet aggregation is a result of the cross-linking of activated
α2bβ3 molecules expressed on two different platelets by fibrinogen (Fig 1)
(Marguerie et al., 1979; Peerschke et al., 1980) at low shear rates or vWF at high
shear rates (Savage et al., 1996; Weiss et al., 1989). α2bβ3 is a platelet
membrane protein of the integrin family and is composed of heterodimers of α2b
and β3 expressed on resting platelets in an inactive conformation. Activation of
integrin α2bβ3 is brought about by inside-out signals that modulate α2bβ3 affinity
by regulating its interaction with intracellular proteins including talin. (Ulmer et al.,
2003; Vinogradova et al., 2000; Vinogradova et al., 2004; Vinogradova et al.,
2002). This transmits information to the cytoplasmic domain of α2bβ3 leading to a
cascade of signaling events which includes the phosphorylation of tyrosine
residues Y747 and Y759 in the β3 cytoplasmic domain. α2bβ3 undergoes a Ca2+
dependent conformational change so that it becomes “fit” to bind fibrinogen.
Inside-out signaling is initiated either by agonists such as ADP or TxA2 through
the G-protein coupled receptors (Brass et al., 1997; Eckly et al., 2001), or by the
adhesive proteins vWF and collagen which interact with GP1b-IX-V or collagen
receptors GPVI and α2β1 respectively.
Once ligands bind to α2bβ3 receptor, it initiates a signaling event from the
integrin into the cell and this is known as outside in signaling. This in turn can
promote firm platelet adhesion, fibrin clot retraction and development of platelet
procoagulant activity and microparticle generation (Kasirer-Friede et al., 2007).
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Recent technical advances have provided a more detailed analysis of
platelet aggregation and the factors involved in the process. Rate of blood flow is
one of the factors that can influence platelet aggregation under different shear
conditions. In conditions of low shear rate, such as veins, fibrinogen binding to
α2bβ3 is the only appropriate mechanism for aggregation; whereas in conditions
of high shear as seen in arterioles or larger arteries, vWF also participates in
adhesion (Savage et al., 1996) or aggregation of platelets (Goto et al., 1998).

Post–aggregation events in platelets:
Formation of a platelet plug at the site of endothelial injury is essential for
hemostasis and can also trigger pathological thrombosis. After the “initiation” of
platelet plug formation by vWF and collagen (Fig 3), extension of the platelet plug
is mediated by agonists released from the platelet granules such as ADP and
TxA2 or thrombin. These agonists by signaling through their respective G-protein
coupled receptors promote platelet aggregation by activating α2bβ3 on the platelet
surface. These bridges can lead to sustained contacts between platelets and
eventual “perpetuation” of the platelet plug (Fig 3). In this context, the phrase
“contact dependent signaling” refers to “intercellular signaling events initiated by
the binding of the proteins on the surface of one platelet to proteins on the
surface of an adjacent platelet, either directly or indirectly” (Brass et al., 2006).
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Fig 3. Steps in platelet plug formation. A) Resting state where PGI2 and NO
form an inert endothelial surface. B) Platelet plug formation is initiated by
exposure of collagen and vWF that causes platelets to adhere to the matrix. C)
platelet plug is extended as more platelets are activated and recruited via the
release of ADP, TxA2 and D) close contacts between platelets and contact
dependent signaling help to stabilize the clot (Adapted from Platelets, Alan D.
Michelson, Academic Press).
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Among the assortment of proteins and signaling molecules involved in
“contact dependent signaling” the most well studied molecule is α2bβ3. Adhesive
proteins can bridge α2bβ3 of one platelet to another, and in the process, not only
strengthens the adhesion but also initiates α2bβ3 mediated outside-in signaling.
However, several other molecules play an important role in this “platelet synapse”
(Fig 4) (Brass et al., 2006). These include receptor tyrosine kinases such as
Ephrins and Eph kinases (Prevost et al., 2005; Prevost et al., 2004); Gas6 and its
tyrosine kinase receptors, mer, tyro3 and axl (Angelillo-Scherrer et al., 2005;
Angelillo-Scherrer et al., 2001); adhesive molecules such as PECAM (Falati et
al., 2006); JAM-1 (Naik et al., 2001); CD40 and its corresponding ligand CD40L
(Andre et al., 2002; Henn et al., 2001) and semaphorins (Zhu et al., 2007) (Fig
4).
An example of this contact dependent signaling is Eph kinase/ ephrin
interactions. Eph kinases are receptor tyrosine kinases with an extracellular
binding domain and an intracellular kinase domain. Eph kinases and their
ligands, known as ephrins are known play a role in axon guidance and
development of the vascular system (Adams and Klein, 2000). Human platelets
express eph kinases Eph A4, Eph B1 and the Eph kinase ligand, ephrin B1
(Prevost et al., 2002). Studies have reported that in platelets Eph A4 and ephrin
B1 interaction modulate platelet-platelet interaction: “forced clustering” of ephrin
B1 or Eph kinases promotes platelet shape change, secretion, adhesion and
aggregation , whereas inhibition of Eph/ephrine interactions leads to “premature
disaggregation” at low agonist concentrations (Prevost et al., 2002). Other
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studies by the same group have concluded that activation of Eph A4 and ephrin
B1 on the platelet surface can support the growth of a stable platelet plug under
flow (Prevost et al., 2003) and at the same time contribute to outside in signaling
through α2bβ3 by assisting tyrosine phosphorylation of β3 chain and probably, a
sustained activation of the integrin (Prevost et al., 2005). This provides
considerable support to the growth and stability of the platelet plug (Prevost et
al., 2005).
In addition to the Eph/ephrin interactions, other laboratories have shown
that platelets express receptors for Gas6, a vitamin K–dependent protein that It
can bind to receptor tyrosine kinases Axl, tyro3, and Mer (Stitt et al., 1995;
Varnum et al., 1995). Gas6 is released form α granules upon initial stimulation of
platelets by agonists. After release, Gas6 could significantly enhance the
formation of stable platelet macro-aggregates by amplifying fibrinogen induced
platelet spreading and irreversible platelet aggregation. Gas6 amplifies by
signaling through its receptors. Activation of Gas6 receptor by Gas6 activates
PI3kinase, granule secretion and stimulates tyrosine phosphorylation of β3
integrin. PI3K in turn, plays an important role in amplifying platelet aggregation
(Kovacsovics et al., 1995; Trumel et al., 1999). Absence of Gas6 or any of its
receptors can protect mice from thrombosis (Angelillo-Scherrer et al., 2001).
Gas6 thus constitutes an important amplification system in pathological
conditions.
Another

important

bioactive

substance

is

CD40L

which

is

a

transmembrane protein that is shed following platelet stimulation (Henn et al.,
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1998). Studies have shown that proteolytic cleavage of CD40L from platelets is
stimulated by its binding to CD40 which is expressed “constitutively on platelets”
(Henn et al., 2001). It was also reported that the soluble CD40L alone could
potentiate integrin mediated platelet aggregation in high shear conditions (Andre
et al., 2002). CD40L null mice exhibited delayed vessel occlusion and abnormally
small platelet thrombi with risks of frequent embolization compared to the wild
type mice (Andre et al., 2002; Crow et al., 2003).
In a continuing search for molecules that might contribute towards contactdependent signaling events during thrombus formation, Zhu et al reported the
role of Semaphorin D (sema4D), an integral membrane protein and the ligand of
two receptors, CD72 and plexin B1. Platelets were shown to express both the
ligand and its receptors, expression of both increased during platelet activation
followed by gradual shedding of sema4D extracellular domain. Platelets from
mice that lack sema4D show impaired collagen induced aggregation responses
in vitro and after vascular injury, showed delayed arterial occlusion in vivo (Zhu et
al., 2007). In the context of the contact dependent signaling, as platelet activation
begins, sema4D that is on the platelet surface is able to interact directly with
receptors on nearby platelets, promoting thrombus formation on exposed
collagen.
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Fig 4. “Platelet synapse” formation and its importance. The initiation of
aggregation brings platelets into close contact with each other so that integrins
and other cell molecules can interact. The space between platelets also provides
a protective environment in which soluble agonists for G protein-coupled
receptors (ADP, thrombin, TxA2) and receptor tyrosine kinases (Gas-6) and the
proteolytically shed bioactive molecules of platelet surface proteins (CD40L and
sema4D) can accumulate (Brass et al., 2006).
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Once thrombus formation begins, contacts between platelets become
increasingly stable and the spaces between the platelets become increasingly
constrained. This provides a protective shelter (Fig 4) for not only the bioactive
molecules shed from the platelet granules (such as ADP and Gas6) but also
those released from the surface of activated platelets (such as CD40L or
sema4D) which can locally accumulate at the site of platelet-platelet contact. All
these contribute to promote the “stability of the hemostatic plug, support clot
retraction and help to maintain the plug till wound healing is complete or at least
under way” (Brass et al., 2004; Prevost et al., 2003).
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CD36
CD36 is an 88kDa glycoprotein belonging to Scavenger Receptor family
Type B (Tandon et al., 1989). It is a member of a family of related genes
including SRBI (scavenger receptor B1) and LIMPII (lysosomal integral
membrane protein). CD36 was identified several decades ago as a protease
resistant platelet surface glycoprotein and named glycoprotein IV for its migration
on SDS-PAGE gel (Clemetson et al., 1977). It was later found to be identical to
the leukocyte differentiation antigen, CD36 a marker for blood monocytes and
tissue macrophages. The CD36 protein sequence is highly conserved across
species. There are several CD36-family homologs in Drosophila; Croquemort,
epithelial membrane protein (emp), sensory neuron membrane protein (SNMP).
Croquemort (“catcher of death”) is expressed on macrophages and hemocytes,
where it is essential for phagocytosis of apoptotic cells (Franc et al., 1996). Emp,
which is expressed “in precursor cells for adult epidermal structures”, has 32%
homology to human CD36 and 34% homology to human LIMP-II (Hart and
Wilcox, 1993). Recently, SNMP was described as another CD36 homologue in
Drosophila and implicated in pheromone detection (Benton et al., 2007).

CD36 expression and its regulation:
CD36 is expressed on a diverse array of cells and tissues including
platelets (Bolin, 1981), mature monocytes (Talle et al., 1983), endothelial cells of
microvasculature (Greenwalt et al., 1990; Swerlick et al., 1992), erythroblasts
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(van Schravendijk et al., 1992), epithelial cells of breast (Greenwalt and Mather,
1985), gut and kidney (Greenwalt and Mather, 1985; Greenwalt et al., 1995;
Susztak et al., 2005) and skeletal muscles (Greenwalt and Mather, 1985). It is
also expressed on phagocytic cells including dendritic cells (Albert et al., 1998),
microglia (Husemann et al., 2002), monocytes and macrophages (Endemann et
al., 1993) and retinal pigment epithelium (Ryeom et al., 1996). CD36 expression
in monocytes has been shown to be highly regulated. It can be upregulated by
adhesion (Huh et al., 1995), M-CSF and IL4 (Yesner et al., 1996) (Huh et al.,
1996), native and oxidized LDL (Feng et al., 2000; Huh et al., 1996), glucose
(Griffin et al., 2001) and endothelin1 (Kwok et al., 2007). CD36 is downregulated
by cholesterol efflux (Han et al., 1999), TGF-β1 (Han et al., 2000),
lipopolysaccharide (LPS) (Yesner et al., 1996), IL10 (Rubic and Lorenz, 2006),
alpha tocopherol (Devaraj et al., 2001; Venugopal et al., 2004). Important
observations by Tontonoz suggested that PPARγ activation in a macrophage cell
line could increase CD36 expression (Tontonoz et al., 1998). These authors have
suggested a mechanism of CD36 induction by PPARγ. In the presence of oxLDL,
CD36 expression on a macrophage leads to intracellular accumulation of
oxidized ligands (9- and 13-hydroxyoctadecadienoic acid [HODE], prostaglandin
J2 [PGJ2]; which in turn activate PPARγ and this cycle continues in a “feedforward loop” (Febbraio et al., 2001) ultimately leading to the conversion of
macrophage into a foam cell.
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CD36: Structure:
In human, mice and rats CD36 consists of 472 amino acids with a
predicted molecular weight of about 53 kDa. However, CD36 is extensively
glycosylated and its apparent Molecular weight on SDS PAGE gel is about
88kDa (Greenwalt et al., 1990; Oquendo et al., 1989). It has 10 potential N
glycosylation sites (Fig 5) which are processed differently in different cell types.
This modification protects the protein from being degraded by cell specific
proteases

or

during

inflammatory

processes

(Febbraio

et

al.,

2001).

Phosphorylation is another post-translational modification reported in CD36.
Asch et al showed by site-directed mutagenesis that CD36 was phosphorylated
in the extracellular loop at position Thr92 (Asch et al., 1993).
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sugar residues
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MEMBRANE
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466cys
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Fig 5. Cartoon showing CD36 structure. CD36 consists of a large, heavily
glycosylated extracellular loop, two trans-membrane domains and two short (α
helical) cytoplasmic tails. The cysteine residues at positions 3, 7, 464 and 466 at
the N and C termini are palmitoylated and help anchoring the protein to the
membrane. Phosphorylation occurs extracellularly at Thr92 residue.

CD36 consists of a hairpin like structure with a large glycosylated
extracellular loop, two α helical transmembrane domains and two short
cytoplasmic tails (Fig 5)(extending residues 1-6 and 167-172 respectively)
(Oquendo et al., 1989; Vega et al., 1991). Very little is known about the
secondary structure of the extracellular loop. The central hydrophilic domain, rich
in N glycosylation sites and in monoclocal antibody epitopes (Daviet et al.,
1995a; Daviet et al., 1995b) lies extracellularly but its exact topology is unknown.
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However, six cysteines residues clustered around the C terminal half of this loop
are proposed to be essential for the maturation and transport of the protein
(Gruarin et al., 2000). A number of studies have contributed significantly towards
our understanding of the CD36 topology. Tao et al reported that CD36 is
palmitoylated at the membrane proximal cysteine residues (positions 3, 7, 464
and 466) in the N and C terminal cytoplasmic tails (Fig 5) suggesting that both N
and C termini are cytoplasmic (Tao et al., 1996). In the same study a C-terminal
truncation

mutant

of

CD36

was

made

which

deleted

the

C-terminal

transmembrane domain. This mutant was found to be membrane-bound when
expressed in human embryonic kidney 293 cells, indicating that the “N-terminal
hydrophobic domain serves as a transmembrane anchor, and thus supporting a
CD36 topology with two transmembrane domains” (Fig 5) (Tao et al., 1996).
Another study by Gruarin et al generated a panel of mutants lacking either
one or both hydrophobic regions and analyzed their folding and transport in
COS-7 cells. The N and the C-terminal hydrophobic regions were both sufficient
to anchor CD36 in the membrane. These results indicated that CD36 adopts a
“ditopic configuration” (Gruarin et al., 2000) as shown in Fig 5.
Binding sites for some of the different ligands have been mapped on
CD36 molecule. Crombie et al have proposed a binding site for TSP-1 termed
the CLESH domain (CD36 LIMP-II Emp sequence homology) (Crombie and
Silverstein, 1998) on CD36 in the region of amino acids 93–120. High affinity
binding sites for oxidized LDL (oxLDL) have been mapped on amino acids 28-93
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(Pearce et al., 1998) whereas another binding site on amino acids 155-183 has
also been reported (Puente Navazo et al., 1996).

CD36: Functions:
CD36 is a multi-functional molecule. It has independent binding sites for
different classes of ligands such as modified phospholipids, thrombospondins,
and free fatty acids. This enables CD36 responsible for several different cellular
processes depending on the nature of the ligand and the type and location of the
cell on which it is expressed. On phagocytes CD36 functions as a scavenger
receptor helping in recognition and internalization of apoptotic cells (Albert et al.,
1998; Fadok et al., 1998b; Greenberg et al., 2006; Ren et al., 1995), Falciparum
malaria infected erythrocytes (Aitman et al., 2000; McGilvray et al., 2000; Omi et
al., 2003; Pain et al., 2001b; Patel et al., 2004; Smith et al., 2003), photoreceptor
outer segments (Ryeom et al., 1996), Staphylococcus aureus (Stuart et al.,
2005), oxidized lipoproteins (Endemann et al., 1993; Febbraio et al., 2000;
Kunjathoor et al., 2002; Rahaman et al., 2006) and non-enzymatically glycated
end products (AGE) (Kuniyasu et al., 2003; Ohgami et al., 2001; Ohgami et al.,
2002).
On adipocytes CD36 was identified as a long chain fatty acid transporter
(Abumrad et al., 1993). It was later found that the C terminus of CD36 is required
for its ability to enhance long chain fatty acid uptake. (Abumrad et al., 1993).
Adipocytes in CD36 null mice failed to accumulate radiolabeled oleate or
palmitate (Febbraio et al., 1999).
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CD36 recognition, binding and uptake of oxidized LDL have been shown
to be critical in cholesterol accumulation and foam cell formation. Cells
expressing CD36 bound and took up oxLDL (Endemann et al., 1993) whereas
CD36-deficient macrophages were resistant to foam cell formation (Febbraio et
al., 2000). The expression of CD36 also could be upregulated by its ligand oxLDL
(Han et al., 1997). A specific region of CD36 in the N-terminal region is said to
contribute to this oxLDL recognition by CD36 (Pearce et al., 1998). In successive
years Podrez et al, in collaboration with our group, have reported that LDL
modified by the myeloperoxidase (MPO) system is highly specific for CD36
binding (Podrez et al., 1999). The MPO system is comprised of MPO generated
reactive nitrogen species. This MPO-modified LDL could form foam cells which
could be significantly inhibited by mAb against CD36 (Podrez et al., 2000). Our
group also identified a highly specific oxidized phosphatidylcholine (oxPC)
possessing a sn-2 acyl group (oxPCCD36) that acts as a high affinity ligand on
oxLDL for recognition by CD36 (Podrez et al., 2002). Other studies by our group
have been instrumental in showing that CD36 is the major receptor on
macrophages for binding and internalization of oxLDL and that although ApoE
mice were pro-atherogenic, ApoE-CD36 double knock out mice were protected
from developing atherosclerotic lesions by about 70-80% (Febbraio et al., 2000).
CD36 also has a very important function in endothelial cell biology. On
microvascular endothelial cells, CD36 is a receptor for thrombospondin 1(Asch et
al., 1987) and 2 (TSP-1 and 2) and mediates their anti-angiogenic activity
(Dawson et al., 1997; Simantov et al., 2005). TSP1 inhibits angiogenesis by
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inducing apoptosis in activated endothelial cells and this requires activation of
CD36, p59fyn, caspase like proteases and p38 MAPK (mitogen–activated protein
kinases) (Jimenez et al., 2000). Elucidation of this signaling pathway would help
plan interventional strategies to inhibit tumor angiogenesis and hence tumor
growth.
CD36 is also expressed on skeletal and cardiac muscles where it
facilitates uptake of fatty acids. In CD36 null mice, injection of a radionuclide
labeled long chain fatty acid (LCFA) analog, such as BMIPP (β methyliodophenyl-pentadecanoic-acid) showed that there was a significant decrease in
fatty acid uptake in skeletal and cardiac muscles compared to wild type (Coburn
et al., 2000). There have been reports describing an increased prevalence of
CD36 deficiency in hereditary hypertrophic cardiomyopathy (Tanaka et al.,
1997b) suggesting an important role of CD36 in fatty acid metabolism in the
heart.
CD36 also functions as an adhesion molecule. Oquendo et al identified
CD36 as the receptor that helps in cytoadherence of Plasmodium Falciparum
parasitized erythrocytes (Oquendo et al., 1989). Pain et al reported that CD36
on platelet mediates clumping of P falciparum infested erythrocytes is strongly
associated with severe malaria (Pain et al., 2001a). In contrast, CD36 on
monocytes or macrophages can help phagocytosis of falciparum infested
erythrocytes (McGilvray et al., 2000). Thus the location of CD36 receptor can
regulate the severity of malarial disease.
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Several studies have suggested an important role of CD36 in phagocytic
clearance of apoptotic and senescent cells. In vitro, expression of CD36 on
fibroblasts and melanoma cells (Ren et al., 1995) confers phagocytic activity by
recognition of apoptotic cells. In vivo, CD36 mediated phagocytosis of apoptotic
cells have observed in photoreceptor outer segments of retinal pigment
epithelium (RPE) (Ryeom et al., 1996) or in dendritic cells (Albert et al., 1998).
Earlier studies have reported interactions between phosphatidylserine (PS)
(Fadok et al., 1998a; Pittoni and Valesini, 2002; Ryeom et al., 1996) on the outer
surface of the apoptotic cells that acts as a recognition ligand for CD36. Recently
we showed that similar to the sn-2 acyl group on oxPCCD36 that are highly specific
ligands for CD36, the sn-2 acyl groups on oxPS could be a highly specific ligand
on apoptotic cells for recognition by CD36 (Greenberg et al., 2006).
CD36 signaling has been very well studied in macrophages where CD36
signals have been known to regulate reactive oxygen species (ROS) formation
(Maxeiner et al., 1998). CD36 probably localizes in lipid rafts (Ehehalt et al.,
2006; Pohl et al., 2005; Ring et al., 2006) with other signaling molecules such as
CD9 (Miao et al., 2001) or integrin (Thorne et al., 2000). Jiminez et al showed
that CD36 dependent fyn phosphorylation together with activation of p38 MAPK
was required for anti-angiogenic activity of TSP-1 on capillary endothelial cells
(Jimenez et al., 2000). Moore et al reported that β amyloid could induce
association of CD36 with lyn and activate a signaling cascade involving the Src
kinase fyn, p44/42 MAPK which in turn induced a macrophage inflammatory
response. Inhibition of lyn kinase inhibited the recruitment of microglial cells to β
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amyloid (Moore et al., 2002). More recently work by Rahaman et al in our lab
illustrated the CD36 signaling in monocytes and macrophages by showing that
CD36-lyn was engaged in a complex with MEKK2 and that uptake of proatherogenic oxLDL was associated with Jnk activation (Rahaman et al., 2006).

CD36 gene:
The CD36 gene extends 32kb on the q11.2 band of chromosome 7
(Armesilla and Vega, 1994). It consists of 15 exons (11 exons in the extracellular
loop) of which 12 are coding and 3 non-coding exons. The regular translation
initiation codon is located at position +290 (exon 3). There is also an ATG codon
within the first exon at position +62 (Armesilla et al., 1996). This ATG codon
might play a role in transcriptional control by acting as a binding site for
transcriptional factors PEPB2/CBF (Armesilla et al., 1996). Sato et al identified
three independent promoters for CD36 gene (Sato et al., 2002; Sato et al., 2007);
CD36 has a wide range of functions in the cell types where it is expressed and
the presence of multiple promoters was partly “to achieve tissue-specific
transcriptional regulation” (Sato et al., 2007). CD36 gene has been most
extensively studied in Asian populations (Japan, Korea, Indonesia, Thailand and
China) where 3-8% of individuals are platelet CD36 deficient (Lin et al., 1993;
Santoso et al., 1993; Seo et al., 1998; Urwijitaroon et al., 1995). This deficiency
was initially observed during the investigation of a Japanese patient who
developed transfusion-refractory thrombocytopenia due to a platelet specific
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antibody and led to discovery that 3-11% of Japanese do not express CD36 on
their platelets (Tomiyama et al., 1990; Yanai et al., 2000). The antibody epitope
on CD36 is called Naka and the individuals lacking GPIV are called Naka minus.
CD36 deficiency is divided in to two subgroups. In type I deficiency,
neither platelets nor monocytes express CD36 while in type II, only platelets fail
to express CD36 (Take et al., 1993; Yamamoto et al., 1990). About 10% of the
Naka minus group are truly null (type I deficiency) where the expression is absent
in platelets, monocytes, endothelium and muscle.
Five mutations have been reported (table 1) to be associated with Type I
CD36 deficiency C478T, 539delAC, 1159insA, 839-841del-->insAAAAC and
1438-1449del accompanied with or without skipping of exon 9 (nt 959-1028) in
Japanese patients (Kashiwagi et al., 1993a; Kashiwagi et al., 1992; Kashiwagi et
al., 1993b). The most common, C478T with an allelic frequency of 80-90% in
CD36 null, produces an amino acid change from proline to serine at position 90
and a misfolded protein that appears to be targeted for intracellular degradation
(Kashiwagi et al., 1993b). The nt539delAC and nt115insA mutations cause a
frameshift, generating a new translation stop codon and reduce CD36 transcripts
in platelets and monocytes to a great extent. The other polymorphisms create
premature stop codons and proteins that are not surface expressed which are
summarized in the table 1 below.
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Table 1: Common polymorphisms accounting for CD36 deficiency

Table 1.Common polymorphisms in CD36 deficient subjects. Table showing
the 5 polymorphisms, which account for more than 90% of CD36 deficiency in
Japan. These polymorphisms cause reduced transcription of CD36 or total loss
of expression due to premature stop codons or proteins which cannot be
processed and presented on the platelet surface.
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The genetic mechanism for type II CD36 deficiency is unclear. About half
of the individuals tested are heterozygous for one of the five common mutations,
but many heterozygous do not have any phenotypes and this probably suggests
that other mutations are involved. The Naka minus phenotype is also highly
prevalent in African and African-American populations with frequencies in the
range of 2.4-7.8% (Curtis and Aster, 1996). Genotyping studies indicate either
homozygous or heterozygous combinations of different mutations other than
those reported in Asia, with a single base substitution T1264G in exon 10 being
the most common (>90%). This encodes a premature stop codon and CD36 is
not expressed on the cell surface.
The Naka minus phenotype is however very uncommon in the Caucasian
population (0-0.3%) (Yamamoto et al., 1990).

This suggests “that selection

pressures existed to maintain or eliminate CD36 null mutation within certain
populations and these may include interaction with pathogens” (Stuart et al.,
2005). One such interaction may be CD36 mediated recognition of P. falciparum
in malaria. The T1264G polymorphism is reportedly associated with protection
from severe malaria in Kenyans (Pain et al., 2001b), although there is a
contradictory report suggesting the susceptibility of T1264G to severe malaria
(Aitman et al., 2000). A study from Thailand showed that in3(TG)12 (12 TG
repeats of intron 3) was significantly associated with the reduction in risk of
cerebral malaria (Omi et al., 2003).
CD36 is a highly polymorphic gene. In addition to the null mutations
mentioned

above,

there

are

multiple
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other

polymorphisms

and

insertions/deletions described, including some in the promoter region that involve
putative transcription factor binding site or in the 5 and 3’ UTR regions. Mutations
specially in the 5’ and 3’ UTR regions are of potential significance since
translational efficiency of CD36 mRNA and CD36 expression levels have been
shown to be regulated by the 5′ UTR (Griffin et al., 2001). In Asia, 9
polymorphisms with allelic frequencies of >15% are known; while in West Africa
40 common SNPs have been identified. In European population, at least 50
SNPs have been identified, including 21 with minor allele frequency of >5%, 11 of
which are in putative promoter region or regulatory UTR regions. More recently,
completion of the Hap Map project gave us access to a huge number of CD36
SNPs in 4 different populations, Japanese, Han from China, Yoruba from Nigeria
and people with European ancestry from Utah, USA (2003). A recent study of
585 residents of eastern Italy using 21 common polymorphisms reported
significant linkage disequilibrium across the entire locus with 2 blocks of
preferential LD, Common haplotypes accounted for >80% of the haplotypes in
each block allowing investigators to use 5 polymorphic markers as tag SNPs
(33137A>G, 31118G>A, 25444G>A, 27645 del and 30294G>C) to classify the
haplotype variability in the population (Ma et al., 2004).
Although the functional impact of CD36 deficiency has been well studied
in different mice and rodent models, the impact of CD36 null mutations and
polymorphisms in human biology is largely unknown. Our lab generated a CD36
knock-out mouse which showed hyperlipidemia (Febbraio et al., 1999) and
insulin resistance (Hajri et al., 2002). In rodent models for CD36 deficiency, diets
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affected phenotypic expression (Aitman et al., 1999). CD36 deficiency has been
found in one strain of spontaneous hypertensive rats (SHR) expressing insulin
resistance (Aitman et al., 1999; Glazier et al., 2002). Because CD36 functions as
a fatty acid transporter in skeletal muscles and adipocytes and because of the
probable link between CD36 null mutation and insulin resistance in the SHR rat,
there has been considerable interest in human type I deficiency and heart
disease and diabetes.
The

relationship

between

CD36

deficiency

and

hypertrophic

cardiomyopathy was reported by several groups in Japan while studying the
cardiac uptake of radionuclide labeled long chain fatty acid (LCFA) analogs, such
as BMIPP (β-methyl-iodophenyl-pentadecanoic-acid) (Tanaka et al., 1997a;
Watanabe et al., 1997a; Watanabe et al., 1998a; Watanabe et al., 1997b;
Watanabe et al., 1998b). Miyaoka et al looked for insulin resistance in genetic
CD36 deficiency, by using a euglycaemic hyperinsulinaemic clamp technique
and reported insulin resistance in the five CD36-deficient people tested. (Miyaoka
et al., 2001). The study from Italy reported that men carrying the common AGGIG
haplotype had 30% higher fasting free fatty acid levels and 20% higher
triglyceride levels than non-carriers. The CAGIG haplotype was associated with
lower levels of circulation free fatty acid levels in this population. The same group
also reported that the overall prevalence of the AGGIG haplotype in diabetics
was not different than non-carriers (Ma et al., 2004). More recently CD36
deficiency in humans was reported to be accompanied by hyperlipidemia and
increased remnant lipoproteins, impaired glucose metabolism due to insulin
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resistance and mild hypertension (Yamashita et al., 2007), all features
suggestive of “metabolic syndrome.” This may be related to defective uptake of
LCFA in the heart (Nozaki et al., 1999; Tanaka et al., 1997a) and increased
uptake of LCFA in the liver (Yoshizumi et al., 2000) which, in turn, may lead to
increased production of VLDL and increased free fatty acid levels in plasma in
these subjects. This may also contribute to insulin resistance.

CD36 on platelets:
CD36 was recognized as a major platelet glycoprotein more than three
decades ago, but its role in platelet physiology has not been studied in great
details. There are about 24000 CD36 molecules per platelet with at least half of
those at the platelet surface (Thibert et al., 1992). Electron microscopy reveals
that CD36 is located on plasma membrane and open canalicular system (OCS)
in platelets (Berger et al., 1993).
A functional role of CD36 on platelets was suggested by the report of
Huang et al according to which CD36 could be co precipitated from platelet
membranes with the non receptor tyrosine kinases fyn, lyn, and yes (Huang et
al., 1991). Interestingly, Naka minus individuals show no evidence of a hemostatic
defect such as bleeding diathesis. Recent reports have shown that VLDL
(Englyst et al., 2003) and amyloid-like protein (Herczenik et al., 2007). increased
platelet activation by the TxA2 pathway. A recent report also links platelet
activation by thrombospondin-1 by inhibition of the NO signaling (Isenberg, 2007
#419) Several reports have linked CD36 autoantibodies with human thrombotic
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diseases, including TTP (Tandon et al., 1994), antiphospholipid antibody
syndrome (Fabris et al., 1994) and lupus (Rock et al., 1994) suggesting that this
phenomenon is clinically relevant.
CD36 is unique among platelet receptors in its ability to recognize a broad
variety of ligands, many of which are generated as a consequence of diseases
with high thrombotic risks. The ligands include oxidized LDL (oxLDL) generated
in atherosclerosis; advanced glycation end (AGE) products generated in
diabetes; membranes of apoptotic cells generated in viral infections and cancer;
and falciparum-infected erythrocytes. Of these, the most extensively-studied
ligand is oxidized LDL (oxLDL) because of its pathogenic role in atherosclerosis.
Systemic conditions with dyslipidemic phenotype is seen in conditions like
diabetes, atherosclerosis and metabolic syndrome and these can predispose to
increased platelet reactivity (Carvalho et al., 1974; Davi et al., 1998). The
mechanisms for increased platelet reactivity in these dyslipidemic states were
largely unknown until recently when our group demonstrated that the
engagement of platelet CD36 by structurally defined oxidized choline
glycerophospholipid ligands (oxPCCD36) could play an important role in the
development of dyslipidemia–associated prothrombotic state. These ligands
were increased in plasma of hyperlipidemic mice and human subjects, were able
to bind platelet CD36 and promote platelet activation in a CD36 dependent
manner. Using in vivo mouse thrombosis models, we also demonstrated that
CD36 null mice were protected from “hyperlipidemia associated platelet reactivity
and the accompanying prothrombotic phenotype” (Podrez et al., 2007). Another
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group demonstrated that low level oxidation (0-15%) of LDL mediated increase
platelet activation involving a p38 MAPK signaling (Korporaal et al., 2005;
Korporaal et al., 2007) while at higher levels of oxidation (>30%) LDL could exert
an opposite effect on platelet activation by interfering with integrin α2bβ3
(Korporaal et al., 2005).
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MICROPARTICLES (MP)
Microparticles are phospholipid microvesicles that bud off normal cells
during either activation or apoptosis (Combes et al., 1999; Jimenez et al.,
2003a). MP were first described by Wolfe in 1967 in platelets when he referred to
them as “platelet dust” (Wolf, 1967). Since their first recognition, several studies
have contributed towards understanding more about MP and their role in
physiology and pathology. In vitro, MP is released from endothelial cells,
platelets, leukocytes, lymphocytes and erythrocytes. In vivo, some of these MP
can be detected in normal or patient human plasma. MP are typically 200 nm1000 nm in size and possess different antigenic properties depending on the type
of cell (endothelium, leukocytes, platelets or cancer cells) from which they are
derived or the process by which they are formed.

Formation of MP:
MP can be produced from cell activation by agonists. In platelets, for
example, maximum MP release is induced by Ca2+ ionophore A23187, followed
by collagen, thrombin and ADP. MP release is also stimulated by the
complement complex C5b-9 or by shear stress (Barry et al., 1997; Gemmell et
al., 1993; Gilbert et al., 1991; Miyazaki et al., 1996; Miyoshi et al., 1996; Siljander
et al., 1996; Sims et al., 1988; Sims et al., 1989; Tans et al., 1991). In endothelial
cells (EC), the process of membrane vesiculation and MP generation has been
shown to follow stimulation by proinflammatory cytokines such as TNFα (Combes
et al., 1999; Jimenez et al., 2003a) or interleukin (IL) 1β and by infectious agents
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or their components such as lipopolysaccharide (Satta et al., 1994). Increase in
membrane calcium is the most critical step for MP release particularly at the site
of release (Ariyoshi and Salzman, 1996). This is further supported by the fact that
chelation of extracellular calcium ions by EGTA blocks the increase in cytosolic
calcium as well as the release of microparticles (Miyoshi et al., 1996). MP
formation probably also requires the breakdown of the membrane skeleton at the
point of release, although this has not yet been elucidated. The formation of
membrane vesicles is also associated with the loss of plasma membrane
asymmetry leading to the exposure of phosphatidylserine (PS) on the outer
leaflet as a consequence of the calcium-dependent activation of scramblase and
floppase (Daleke, 2003; Zwaal and Schroit, 1997).
MP can also be released from apoptotic cells. Apoptosis is characterized
by “cell contraction, DNA fragmentation and dynamic membrane blebbing”
(Coleman et al., 2001). Apoptotic membrane blebbing is regulated by caspase3
induced Rho-kinase I activation (Sebbagh et al., 2001).

Importance of release of MP:
There has been considerable speculation about why cells release MP. MP
may be released as messengers, to transfer receptors or proteins or to initiate
signaling events. The release of MP would also allow cells to escape
phagocytosis by removing death signals (“eat me signals”) such as
phosphatidylserine (Fadok et al., 2000; Simak and Gelderman, 2006) from their
surface.
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Composition of microparticles:
MP are composed of mainly proteins and lipids. The composition depends
on the cell they originate from and the type of stimulus involved in their formation.
For example, phospholipid composition of MPs isolated from synovial fluid of
patients with rheumatoid arthritis differs from that of MPs isolated from the
plasma of healthy subjects (Fourcade et al., 1995). MPs also express proteins
that are specific to the cell that they originate from and this characteristic can be
used to determine their parental source by using antibodies directed against
these specific antigens. For example, endothelial microparticles (EMP) released
upon activation or apoptosis differ considerably in terms of antigenic expression
(Jimenez et al., 2003b). Those expressing constitutive markers such as CD105
and CD31 are greatly increased in number in apoptosis while those expressing
inducible markers such as CD62E, CD54 are increased in activation.

Function

A) Effect on blood coagulation system:
MP undergo a loss of membrane asymmetry during their formation and
thus characteristically express phosphatidyl serine (PS) on their surfaces. This
may contribute to thrombosis by acting as a catalytic surface for assembly of the
prothrombinase complex (Sims et al., 1989). MPs are procoagulant not only
because of the presence of anionic phospholipids on their surface but also
because they are major carriers of blood borne tissue factor (TF). There have
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been reports of monocyte derived MP that contain TF, P selectin glycoprotein
ligand (PSGL-1, a protein that binds to P selectin) in human platelet poor plasma
(Falati et al., 2003). P selectin and TF both play a very important role in thrombus
formation. Both cell surface P selectin on activated platelets and endothelial cells
and P selectin shed from these cells bind to PSGL-1 in the monocytes and this
induces formation of TF-positive MP (Falati et al., 2003). P selectin on the
activated platelets helps in the recruitment of these MP to the thrombus by
binding to PSGL-1 on the MP (Celi et al., 2004). This ultimately leads to
increased thrombin generation at the site of injury.

B) Effects of MPs on platelets, leukocytes and endothelial cells
Circulating MP have been shown to interact with platelets, leukocytes and
endothelial cells (Morel et al., 2006) and may influence cell activation. Endothelial
derived MP (EMP) from TNFα stimulated EC, for example, not only bound to
human monocytes and monocytic cell lines via intracellular adhesion molecule
(ICAM)-1 expressed on EMP, but also stimulated TF expression and
procoagulant activity on the cells (Sabatier et al., 2002). Platelet MP bind,
activate and aggregate neutrophils in vitro (Lo et al., 2006). In addition, another
study showed that platelet MP increased the adhesion of monocytes to
endothelial cells (Barry et al., 1998). A recent study showed that platelet MPs
may act as carrier for arachidonic acid from pulmonary endothelial cells and this
arachidonate is subsequently metabolized by MP to TxA2 (Pfister, 2004).
Besides arachidonic acid, PAF, another potent mediator was documented in
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platelet derived and PMN derived MPs (Iwamoto et al., 1996), potentially
contributing towards platelet activation.

C) Microparticles as markers in diseases
MP have been postulated to play an important role in inflammation
(Soriano et al., 2005), atherosclerosis (Falati et al., 2003) and thrombosis, and in
part related to tissue factor (TF) and selectins expressed on their surface (Falati
et al., 2003).
Endothelial Cell (EC)-derived MP (EMP) have been found in the blood of
patients with thrombotic and inflammatory disorders. These include lupus
anticoagulant (Dignat-George et al., 2004), coronary artery disease (CAD)
(Bernal-Mizrachi et al., 2003; Werner et al., 2006), diabetes mellitus (Davi and
Ferroni, 2005; Koga et al., 2005), thrombotic thrombocytopenic purpura (Jimenez
et al., 2001), active multiple sclerosis (Minagar et al., 2001), hypertension
(Gonzalez-Quintero et al., 2004), or after hematopoietic stem cell transplantation
(Pihusch et al., 2006).
Platelet derived microparticles (PMP) correlate with early phase of
myocardial infarction and atherosclerosis (van der Zee et al., 2006), in patients
with intermittent claudication (Tan et al., 2005), in stroke (Lee et al., 1993), deep
vein thrombosis (Rectenwald et al., 2005) or sickle cell anemia (Shet et al.,
2003).
The different studies mentioned above clearly demonstrate that the
detection and characterization of MP is an interesting and valuable tool to
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diagnose certain disease states and perhaps also function as risk calculator for
certain cardiovascular conditions.
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HYPOTHESES
CD36 on macrophages can initiate signals that play a significant role in
fatty streak formation. The function of CD36 on platelets is incompletely
characterized, but our group has recently shown that atherogenic oxidized LDL
(oxLDL) binds and activates platelets in a CD36-dependent manner (Podrez et
al., 2000). We also demonstrated that CD36-dependent phagocyte recognition
and uptake of apoptotic cells and/or shed photoreceptor outer segments was
mediated by binding of CD36 to PS and/or oxPS on their surfaces (Greenberg et
al., 2006; Ryeom et al., 1996; Sun et al., 2006). Since MP express PS on their
surface, we hypothesized that they might also act as a ligand for platelet
CD36 and thereby promote platelet activation. In a clinical scenario where MP
are formed, such as in inflammation, cancer, atherosclerosis or thrombosis,
CD36-mediated platelet signaling might contribute to pathological thrombosis.
There has been evidence to suggest that there is significant population
variance in CD36 expression. When we studied a small group of study subjects,
we observed that there was considerable variation in CD36 expression (Fig17,
chapter IV). We thus also hypothesized that the variability in CD36 expression
on platelets might affect platelet function and that part of this variability
might be explained by genetic polymorphisms.
In the Caucasian study reported by Ma et al (Ma et al., 2004), the
phenotype (increased triglycerides and FFA) associated with the AGGIG CD36
haplotype is consistent with a decrement in CD36 function. No direct data,
however, exists to support this. Since CD36 is a fatty acid transporter in heart
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muscles and adipocytes, we hypothesized that there may be a relationship
between CD36 polymorphisms and its expression and function.
In summary, we propose a novel mechanism for modulation of platelet
reactivity by the surface receptor CD36 with specific ligands generated during
disease

states

associated

with

increased

risk

of

arterial

thrombosis.

Determination of the molecular and genetic mechanisms that control this
pathway would help us to a) discover novel methods to diagnose these events
and b) design novel preventative strategies to control these events.
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CHAPTER II
MATERIALS AND METHODS

Preparation of platelets and platelet rich plasma:
Whole blood was collected from healthy human volunteers in 0.109 M sodium
citrate, 7.4 pH (1:9 dilution) in accordance with the Cleveland Clinic Institutional
Review Board. These donors had no known disease and were not taking aspirin,
non steroidal anti-inflammatory drugs (NSAIDs) or any other medication. Platelet
rich plasma (PRP) was obtained by centrifugation at 100g for 12min at room
temperature.

Platelets were counted in a Z2 particle counter (Coulter) and

platelet number adjusted to 2x108/ml for all aggregometry experiments. For flow
cytometry experiments, washed platelets were prepared by centrifuging PRP at
600g for 10min in the presence of 10 mM prostaglandin E1 (PGE1). PGE1
prevents any platelet activation by ADP during the process of centrifugation. The
pellet was washed twice with Modified Tyrode’s Buffer and then resuspended in
this buffer at a concentration of 1X106/ml.
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Detection of platelet CD36 expression:
100 μl of PRP from healthy normal donors were incubated with either PEconjugated anti-CD36 monoclonal antibody (Santa Cruz) or isotype matched
control antibody. CD36 expression was determined by flow cytometry by gating
platelets with an anti-CD42b monoclonal antibody (BD Biosciences) and also on
forward versus side scatter, followed by gating on PE-fluorescence vs. forward
scatter for CD42b/CD36 positive events.

Generation of endothelial derived microparticles (EMP):
Human EC were isolated from umbilical veins and maintained in culture as per
Jaffe et al (Jaffe et al., 1989). Cells of second passage were typically used for
experiments and were incubated with 100 ng/ml TNFα (R&D Systems) and 50
ug/ml cyclohexamide (Sigma) for 24hr (Simak et al., 2002) to generate EMP.
Culture supernatants were collected and nonviable cells and large cell fragments
were removed by centrifugation at 4300g for 5min. The supernatants were then
centrifuged at 100,000g for 90min at 10°C to pellet EMP. Pelleted EMP were
resuspended in 100ul HEPES-Tyrode’s buffer (137 mmol/L NaCl, 2.8 mmol/L
KCl, 1.0 mmol/L MgCl2, 12 mmol/L NaHCO3, 0.4 mmol/L Na2HPO4, 0.35%
bovine serum albumin (BSA), 10 mmol/L HEPES, 5.5 mmol/L glucose, pH 7.4)
and stored at -70°C. Freezing and thawing had no adverse effect on size or
morphology of the EMP as assessed by immunofluorescence microscopy. EMP
were characterized by flow cytometry (PCA Analyzer, GUAVA Technologies) and
shown to bind FITC-conjugated annexin V (BD Biosciences) and phycoeryrthrin
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(PE)-conjugated antibodies to CD105/endoglin (Ancell), VE-cadherin (BD
Biosciences), and CD31 (BD Biosciences). In all cases, corresponding isotype
matched non-immune IgGs were used as controls. CD105 positive EMP were
counted by flow cytometry using 0.3 and 3 µm latex beads (Sigma) as size
standards. Each confluent T75 flask of cells generated approximately 3x105
CD105 positive EMP.
Isolation of MP from human plasma:
Human blood was isolated from healthy normal and centrifuged at 500 g to
obtain platelet poor plasma (PPP). The PPP was then centrifuged at 15000 g for
45 minutes at 20°C to pellet the MP which were resuspended in Modified
Tyrode’s buffer containing 0.35% BSA and stored at -70°C. Human MP were
heterogenous and some expressed endothelial (CD105 and CD144), platelet
(CD41), monocytic (CD14) markers. Each marker was separately counted by
flow cytometry. Our colleague, Dr. McCrae, analyzed 105 subjects and a
representative group of 13 was used for experiments.

Preparation of oxidized LDL (oxLDL):
OxLDL was prepared by oxidation with copper sulphate (5µm) at 37˚C for 6
hours according to a previously published protocol (Febbraio et al., 2000). The
amount of lipid oxidation that had taken place in each LDL sample was assessed
using the TBARS (thiobarbuturic acid-reactive substances) assay (Morel and
Chisolm, 1989).
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Immunofluorescence flow cytometry detection of platelet-MP interactions:
Washed platelets were incubated with MP for 30min prior to incubation with the
EC-specific anti-CD105 antibody. After antibody incubation, cells were pelleted,
washed and analyzed by flow cytometry.

Relative fluorescence intensity

histograms and dot-plots were made and analyzed with Flow Jo software (Tree
Star, Inc). For the MP binding studies, we used anti-CD105 antibody which is
specific for endothelial cells. EMP but not platelets would bind anti-CD105.
Washed platelets were pre-incubated with MP at a ratio of 1:9 for 30 minutes, the
reaction mix was then centrifuged at 700g, a speed that would pellet only the
platelets and washed to get rid of any free EMPs. When the resuspended pellet
was incubated with anti-CD105, the platelets acquired fluorescence suggesting
that CD105-positive MP were physically associated with the platelets and the
change in platelet acquired anti-CD105 fluorescence was measured and
statistically quantified. In some studies, platelets or MP were incubated with
antibodies, oxLDL, or Annexin V (BioVision) prior to CD105 staining. Blood
collection, MP incubation, antibody incubation, and data acquisition for all
samples were done on the same day, using the same instrument for each
individual experiment for consistency. Univariate analyses were performed using
analysis of variance (ANOVA) and paired and unpaired t-tests, as appropriate.
Data are presented as mean ± SD. Statistical significance was defined as
p<0.05.

Statistical analyses were performed using commercially available

software (StatView 5.0; Abacus Concepts Inc, Berkley, CA).
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Immunofluorescence microscopy:
For immunofluorescence microscopy, platelets were loaded with an intracellular
green fluorophore (Calcein, Molecular Probes) and EMP with a red fluorophore
(PKH-26, Sigma) and incubated together as above prior to imaging with a Leica
DM-RXE microscope, interfaced to a PC using Q capture software (Quantitative
Imaging Company).

Platelet activation studies:
Washed platelets (1x106) were incubated with EMP (1:9 ratio) or buffer control for
30min and then stimulated with ADP. In case of human MP, numbers were
normalized on the basis of endothelial markers. They were then incubated for 15
mins with PE-conjugated anti-P-selectin IgG (BD Biosciences) or FITCconjugated PAC1 (BD Biosciences), a monoclonal antibody that recognizes the
activated conformation of the platelet integrin α2bβ3. After incubation, the platelets
were centrifuged at 700 g for 10 min, resuspended in PBS, and analyzed by flow
cytometry. In some studies, washed platelets were pre-incubated with antihuman CD36 antibody (clone FA6, Invitrogen) or isotype matched control IgG
(Sigma).

Platelet aggregation studies:
Platelet aggregation was assessed turbidometrically with a dual channel
aggregometer (Chronolog Corporation, PA) using graded doses of ADP from 1-
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20 µM under constant stirring conditions. The light transmission of PPP was
regarded as 100% aggregation and the light transmission of PRP before addition
of agonist was regarded as 0%. Any change in light transmission after addition
of agonist was recorded and expressed as a percentage of deflection.

Intravital thrombosis:
Carotid arteries in wild type and CD36 knock out mice were visualized on a Leica
DM LFS microscope with water immersion objectives and recorded images with
a high speed color, cooled digital camera (QImaging Retiga EXi Fast 1394) with
Streampix high-speed acquisition software. We recorded the blood vessels for 30
minutes and then created a vessel- wall injury by application of a 1.5 x 1.5 mm
square of Whatman filter paper soaked in saturated FeCl3 solution to the surface
of the vessel (we used 12.5% FeCl3 for 1 minute).Then we removed the paper,
covered the vessel with saline at 37˚C and recorded platelet-vessel wall
interactions for 15 minutes. The thrombosed arteries were sectioned and frozen
at -20˚.

Immunofluorescence staining:
Frozen thrombosed carotid sections were used for immunohistochemistry to
detect endothelial derived microparticles (primary CD105; secondary, Alexa Fluor
568) and platelets (marker primary,CD61; secondary, Alexa Fluor 488) or both.
Cryosections of thrombosed carotid were thawed at room temperature, post fixed
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in acetone and hydrated in PBS. Tissues were blocked for 1 hour at room
temperature with BSA, followed by incubation with 1:200 dilution of CD61
antibody and subsequently with 1:500 dilution of AlexaFluor 488. The same
slides were also stained with CD105 antibody (1:500 dilutions) followed by Alexa
Fluor 568 conjugated secondary. Confocal imaging was acquired with Leica
TCS-SP2 confocal microscope (Leica Microsystems, Heidelberg) at room
temperature using 63X lens. Using Adobe Photoshop software, histograms were
linearly adjusted for optimal representation of the 8 bit signals, individuals
channels were overlaid in RGB images and composites of panels were made for
final figures.

Western Blot analysis:
Human platelets were lysed and resuspended in lysis buffer ( Tris, pH 7.5 20mM,
NaCl 100mM, EDTA 1mM, EGTA 1mM, Triton x 1%) containing protease
inhibitors. Proteins (20 µg) were separated by SDS-PAGE and transferred to
PVDF membranes (Immobilon-P, Millipore). CD36 was identified using a
monoclonal antibody (clone FA6, Invitrogen). Membranes were reprobed with an
antibody with actin (Santa Cruz) or GPIX (Santa Cruz) to normalize for protein
loading. Detection was performed with ECL plus Western Blotting Detection
Reagents (Amersham Biosciences) and band intensity was analyzed by
densitometry (Image J). Experiments were done twice in duplicate and
normalized readings expressed as mean ± S.E.
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OxLDL induced platelet activation:
Washed platelets (1x106) were incubated with oxLDL (50ug/ml) or native LDL
(control) for 30min and then stimulated with or without ADP. They were then
incubated for 15 minutes with PE-conjugated anti-P-selectin IgG (BD
Biosciences) or FITC-conjugated PAC1 (BD Biosciences), a monoclonal antibody
that recognizes the activated conformation of the platelet integrin α2bβ3. After
incubation, the platelets were centrifuged at 700g for 10min, resuspended in
PBS, and analyzed by flow cytometry. Results are representative of at least 2
independent experiments.

Study population:
The initial screen included 32 healthy human volunteers. This was followed by a
larger patient population who came to Cleveland Clinic Cardiac Catheterization
lab, agreed to participate in a study and the blood was collected by GeneBank.
GeneBank is a large cardiovascular genetic repository in Cleveland Clinic
Foundation which is involved in prospective collection of DNA, plasma and serum
as well as maintenance of an extensive database of deidentified patient records.
We have used 550 patients from this diverse population. Each sample was
collected fresh and deidentified before use.

Tagged SNPs:
Using the haploview software offered at the international HapMap consortium
website, we identified 10 SNPs with allelic frequencies >5% that “tag” major
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areas of linkage disequilibrium. 10 SNPs were picked out for population CEU
(population from Utah, USA with European descendency) using the algorithmTagger-pairwise tagging (Carlson et al., 2004; Chapman et al., 2003). The mean
r2 cut off for the tagging was 0.8.

Table 2: Identification of 10 tagged SNPs

number

#tag SNPs

Chromosome Position

MAF

1

rs10499858

chr7

79880497

0.108

2

rs6968407

chr7

79882768

0.342

3

rs10499859

chr7

79903461

0.492

4

rs9918586

chr7

79911387

0.091

5

rs3211864

chr7

79930995

0.05

6

rs3211869

chr7

79931803

0.119

7

rs3211908

chr7

79938567

0.108

8

rs3211932

chr7

79943538

0.483

9

rs1527483

chr7

79946151

0.158

10

rs1537593

chr7

80091847

0.134

Table 2: Tag SNPs. Table showing the 10SNPs with minor allelic frequency (MAF) of
5%.Also shows the position of each SNP. The numbers were allocated according to the
position of the SNPs. In haplotype analyses, these numbers were used rather than the
SNP designation.
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SNP genotyping:
Genotyping of SNPs was carried out by the 5’allelic discrimination assay (the
TaqMan assay) as described previously (Shen et al., 2007). SNP assay probes,
Assay-on-Demand or Assay-by-Design, were from Applied Biosystems (ABI,
Foster City, CA, USA). PCR for SNP genotyping was performed in a 5 μl volume
containing 20ng of genomic DNA sample and 2 μl TaqMan Universal PCR
Master Mix a GeneAmp PCR System 9700. The PCR products were scanned by
an ABI PRISM 7900HT Sequence Detection System. Alleles of SNPs were called
analyzed with software version 2.1. For quality control, SNP genotyping results
were verified for eight random selected DNA samples by direct DNA sequence
analysis as described (Shen et al., 2007). DNA sequence analysis was
performed by Big Dye Terminator Cycle Sequencing v 1.1 Mix (ABI, Foster City,
CA, USA) using ABI 3100 Genetic Analyzer.

Genetic Data analysis:

A) SNP analysis:
The mean fluorescence intensity of CD36 expression on platelets was
categorized into 2 groups by their median (< 3.75 or > 3.75). We generally
considered phenotypes as outcomes and SNPs as predictors. If outcome was
binary, we used fisher exact test of the association and calculated OR (Odds
Ratio) by logistic regression. If the outcome was multilevels, we used trend test
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or the linear-by-linear association tests (Agretsi, 2002; Horthorn, 2006) R coin
package: independence test) to test the association between the SNPs and
traits. We fitted proportional odds ordinal logistic regression models, which apply
maximum likelihood estimation or penalized maximum likelihood estimation
(Agretsi, 2002; Harrel, 1998; R) to estimate the ratio of the cumulative odds of
the upper quintiles and lower quintiles of the traits. Since we were testing the
associations

of

10

SNPs

simultaneously,

we

considered

the

multiple

comparisons adjustment, where we implemented a correction introduced by
Benjamini & Hochberg (Benjamini and Hochberg, 1995) controlling the false
discovery rate (FDR), the expected proportion of false discoveries amongst the
rejected hypotheses. The FDR is a less stringent condition than the family wise
error rate (FWER), so it is more powerful than those controlling FWER. Only
those with P values < 0.05 and FDR values < 0.2 were reported as statistically
significant findings.

B) Haplotype analyses:
We applied the ‘haplo.stats’ package in R (Schaid et al., 2002) (http://cran.rproject.org/src/contrib/Descriptions/haplo.stats.html) to identify the association
between a trait and haplotypes. A suite of R routines, referred to as
“haplo.score”, was used to compute score statistics to test associations between
haplotypes and traits. “haplo.score.slide” was used to identify sub-haplotypes
from a group of loci. It is useful for a series of loci where little is known of the
association between a trait and haplotypes.
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We first ran “haplo.score.slide” on all contiguous SNP subsets of size,
n.slide. Using a range of n.slide values (=2,3,4,5), the region with the strongest
association consistently have low p-values for locus subsets containing the
associated haplotypes.
For each phenotype, we considered different SNPs subsets with a range
of n.slide values, which meant that we were testing the associations of multiple
subsets (30 subsets) simultaneously. Therefore, we need to consider the multiple
comparisons adjustment. We considered two error measures: the false discovery
rate (FDR) and the tail probability of the proportion of false positives (TPPFP).
We used Bonferroni procedure to get adjusted p-values, then applied
augmentation approach to these p-values to get generalized TPPFP adjusted pvalues (van der Laan, 2004, 2). Also we considered a multiple comparisons
adjustment implemented by Benjamini & Hochberg correction to control FDR. We
report the SNP subsets with TPPFP adjusted p-values less than 0.2 have
statistically significant association with the trait.
For each of these significant SNP subsets, we ran “haplo.score” to identify
the haplotypes which are significantly associated with the trait. We considered
those haplotypes with p values of score tests less than 0.05 as potential
significant ones.
To calculate the odds ratio of the significant haplotypes for the specific
phenotype, we applied the “haplo.glm”. The base haplotype is the most frequent
one.

53

CHAPTER III

ENDOTHELIAL DERIVED MICROPARTICLES BIND AND ACTIVATE
PLATELETS IN A CD36 DEPENDENT MANNER

Characterization of EMP:
Human EC were isolated from umbilical veins were incubated with 100 ng/ml
TNFα and 50 ug/ml cyclohexamide overnight to generate EMP. EMP were
characterized by flow cytometry and shown to bind FITC-conjugated annexin V
(a marker for surface PS) and phycoeryrthrin (PE)-conjugated antibodies to the
EC specific proteins CD105/endoglin, VE-cadherin, and CD31 (BD Biosciences)
(Fig 5). In all cases, corresponding isotype matched non-immune IgGs were
used as controls. As CD105 gave most robust fluorescence, it was used for the
subsequent assays.
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Fig 6. Characterization of EMP. HUVECs were treated with TNFα and
Cyclohexamide and EMP were obtained from the supernatant. Flow cytometry
histograms of EMP shown to bind FITC-conjugated annexin V and phycoeryrthrin
(PE)-conjugated antibodies to CD105/endoglin, VE-cadherin, and CD31 (BD
Biosciences).

EMP bind to platelets:
As shown in Fig 7A, EMP but not platelets (Fig 7B) bound anti-CD105. When
washed platelets were pre-incubated with EMP prior to incubation with antiCD105, the platelets acquired fluorescence (Fig 7B), suggesting that CD105positive EMP were physically associated with the platelets.
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This physical

association was confirmed using 2-color fluorescence microscopy (Fig 8): EMP
were labeled with a red fluorophore (Fig 8A, bottom panel) and platelets were
labeled with a green fluorophore (Fig 8A, top panel). As shown in Fig. 8B, the
red EMP formed rosettes with the green platelets.

Fig 7. CD36-dependent binding of EMP to platelets detected by
immunofluorescence flow cytometry. EMP were generated and purified from
HUVEC cultures treated with TNFα (100ng/ml) and cyclohexamide (50μg/ml) for
24hrs. (A) Flow cytometry histogram showing that EMP stain with a PEconjugated anti-CD105 IgG (solid line) but not an isotype matched control IgG
(dotted line). (B) Flow cytometry histogram showing that platelets did not react
with the anti-CD105 IgG (dotted line) but when incubated with EMP at a ratio of
1:9, the platelets acquired PE fluorescence (solid line). (C) Platelets and EMP
were mixed together and stained with anti-CD105 IgG as in panel B, except the
platelets were first pre-incubated with anti-CD36 IgG FA6 (dashed line); or (Panel
D) isotype matched control IgG (dotted line). (E) Platelets and EMP were mixed
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together and stained with anti-CD105 IgG as in panel B, except platelets were
from a donor shown to be CD36 null. Platelet-associated PE fluorescence was
reduced by more than 95%. In all cases histograms represent one of at least 3
separate experiments.

EMP binding to platelets is CD36 dependent:
We used two independent methods to define the role of CD36 in platelet-EMP
interactions. As shown in Fig. 7C, pre-incubation of washed platelets with a
monoclonal anti-CD36 antibody inhibited the acquisition of anti-CD105 positivity
in a flow cytometry assay; control IgG had no effect (Fig 7D). Similarly, using
immunofluorescence microscopy, oxLDL, an alternative ligand for CD36 (Fig. 8C)
or antibody to CD36 (Fig. 8E), inhibited platelet-EMP interaction whereas control
IgG (Fig 8F) and native LDL (Fig 8D) had no effect.

Furthermore, platelets

isolated from a CD36 null donor did not bind EMP (Fig 7E).
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Fig 8. CD36-dependent binding of EMP to platelets detected by
immunofluorescence microscopy. (A) Washed platelets (top panel) were
loaded with calcein and visualized by green fluourescence. EMP (bottom panel)
were loaded with PKH26 and visualized by red fluorescence. (B) Platelet-EMP
rosettes seen when calcein-loaded platelets and PKH26-loaded EMP were
incubated together at a 1:9 ratio for 30min prior to visualization. (C) Fluorescence
tagged platelets and EMP were mixed together as in panel B except that
platelets were first incubated with oxLDL (50µg/ml) or (D) nLDL (50ug/ml) as
control or (E) an inhibitory anti-CD36 IgG or (F) its IgG control prior to
visualization.
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Blockade of MP-PS inhibited platelet-MP interaction:
Incubation of MP with annexin V to block exposed PS dramatically reduced
platelet acquired CD105 fluorescence (Figure 9A). A control protein, thioredoxin,
had no effect. In addition, incubation of MP with a monoclonal anti-PS antibody
significantly reduced the platelet-MP interaction whereas a non-immune control
IgM did not (Figure 9B). These data suggest that the ligand for CD36 on the MP
surface is phosphatidylserine.
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Fig 9. Binding of EMP to platelets is PS dependent. Platelets and EMP were
mixed together and stained with anti-CD105 IgG as in Figure 1B, except the EMP
were first pre-incubated with annexin V (150nmol) to block exposed PS. Platelet
associated anti-CD105 fluorescence was reduced by >95% (Figure 9A). Preincubation of EMPs with thioredoxin, a control protein had no effect. Similarly,
EMP preincubated with anti PS antibody (25µg/ml) were mixed with platelets and
stained with CD105. The platelet associated fluorescence was significantly
reduced (Figure 9B, dashed line) whereas the control IgM had no effect (Figure
9B, dotted line) .The histograms are representative of at least 2 separate
experiments.
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EMP enhance platelet activation and aggregation:
To assess the functional consequences of EMP-platelet CD36 interactions, we
incubated PRP with EMP prior to assessment of activation and aggregation
responses to graded concentrations of the agonist ADP. EMP at a ratio of 1:9 (9
EMP per platelet) did not induce platelet aggregation (not shown). In contrast, in
combination with low doses of ADP, EMP induced a significant increase in the
rate and extent of the aggregation response (Fig 10A). This effect was not
observed in platelets from CD36 null donors (Fig 10B) demonstrating CD36
dependence. Fig.10C shows that EMP significantly enhanced the extent of
aggregation of CD36 expressing platelets induced by ADP concentrations of 1-4
µM but not 20 µm (white and black bars). No EMP effect was observed at any
ADP concentration in CD36 null platelets (hatched and checkerboard bars). We
also observed that responses of CD36 expressing platelets to graded doses of
ADP (1-20µM) were significantly higher than those of CD36 null platelets (white
and hatched bars).
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Fig 10. CD36-dependent enhancement of platelet aggregation by EMP in
response to low doses of ADP. EMP were added to PRP obtained from
healthy CD36 expressing (A) or CD36 null (B) donors and then stimulated with
2μM ADP. Aggregration was assessed turbidometrically with a dual channel
aggregometer. Tracings show representative aggregometry curves from n=4.
(C) Maximum aggregation response of CD36 expressing platelets (open and
closed bars) and CD36 null platelets (hatched and checkerboard bars) incubated
with EMP (closed and checkerboard bars) or with buffer control (open and
hatched bars) in response to graded doses of ADP. Values are the means of
measurements done in triplicate from CD36 expressing or null donors and are
expressed as +/- SE. Significant differences between CD36 expressing platelets
with(open bar) or without(closed bar) prior incubation with EMP are shown by(*)
sign. Significant differences between ADP dose responses between CD36
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expressing (hatched bar) and CD36 null platelets (checkerboard bar) are shown
by (#) sign.

EMP enhance platelet activation and secretion:
To determine the effect of EMP on platelet activation and secretion, we assessed
platelet P-selectin expression, a marker of α-granule secretion (Fig 11A) and
PAC1 binding, a marker of integrin α2bβ3 activation (Fig 11B) in response to 2
µM ADP. In both cases we observed that EMP induced a marked increase in the
expression of these markers. These effects were significantly diminished by preincubation of platelets with anti-CD36 IgG (Fig 11A and 11B).

Furthermore,

washed platelets from a CD36 null donor showed neither increased P-selectin
expression nor PAC1 binding in the presence of EMP and 2 µM of ADP (Fig 11C
and 11D).
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Fig 11. CD36-dependent enhancement of platelet activation by EMP in
response to low dose ADP. Washed platelets from CD36 expressing donors
(A) and (B) or CD36 null donors (C) and (D) were incubated with EMP (1:9) or
buffer control for 30min and then stimulated with 1μM ADP. They were then
incubated with either PE-conjugated anti-P-selectin (A) and (C) or FITCconjugated PAC1 (B) and (D) and analyzed by flow cytometry. (A and B)
Histograms showing increased anti-P-selectin (A) and PAC-1 (B) binding to
CD36-expressing platelets when pre-incubated with EMP. Binding was
significantly decreased when platelets were pre-incubated with anti-CD36 IgG,
but not an isotype matched control IgG. (C and D) Histograms showing lack of
increased anti-P-selectin (C) or PAC-1 (D) binding to CD36 null platelets when
pre-incubated with EMP. Histograms are representative of three independent
experiments.
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Isolation and characterization human blood-derived MP:
Human MP (MP) were characterized by endothelial (CD105 and CD144), platelet
(CD41), monocytic (CD14) markers and each marker was separately counted by
flow cytometry. Our colleague, Dr. McCrae analyzed 105 subjects and a
representative group of 13 subjects was used for experiments.
Table 3: Characteristics of MP isolated from normal human plasma
donor
donor 1

Annexin V APC

CD 105 PE

CD 14 PE

CD 41 PE-Cy5

14730

6030

1980

900

donor 2

180

270

90

450

donor 3

8190

3960

1125

17440

donor 4

9450

4865

225

23940

donor 5

9630

2655

720

2250

donor 6

13950

1485

585

1680

donor 7

360

180

135

2295

donor 8

5040

4500

315

2520

donor 9

540

3420

135

1710

donor 10

5490

2025

90

1350

donor 11
donor 12

NA
8820

8963
2025

12
675

13249
20644

donor 13

10170

1710

720

22470

Mean ± SD

7213±4988

3238±2453

524±352

8531± 9412

Table 3: Characteristics of MP isolated from blood of normal human
subjects. MP were isolated from platelet poor plasma of normal human
subjects. Human MP were analyzed by flow cytometry and were quantified by
light scatter and annexin V staining. MP were also characterized by cell of origin
using antibodies to endothelial: (CD105), platelet (CD41) and monocytic (CD14)
markers. Each marker was separately counted by flow cytometry. Also shown
here are the average count per ml ± SD for each MP marker. We analyzed 105
subjects and a representative group of 13 was used for experiments. NA: not
available
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MP isolated from normal healthy subjects bind and activate platelets in a
CD36-dependent manner:
As noted by others (Berckmans et al., 2001; Jimenez et al., 2001; Simak et al.,
2002), MP can be isolated from healthy subjects with no thrombosis history or
risk. MP isolated from 13 healthy human subjects were used for the studies
discussed below. As shown in Figure 6A, MP isolated from normal healthy
volunteers stained positively for CD105.

When washed platelets were pre-

incubated with human plasma derived MP at a ratio of 9 MP per platelet prior to
incubation with anti-CD105, the platelets acquired fluorescence (Figure 12B),
suggesting that CD105-positive MP were physically associated with the
platelets. To determine the effect of blood borne MP on platelet activation, we
assessed platelet PAC1 binding, a marker of integrin α2bβ3 activation (Figure
12C) in response to 2 µM ADP. Human plasma-derived MP induced a marked
increase in the expression of PAC1. This effect was significantly diminished by
pre-incubation of platelets with anti-CD36 IgG (Figure 12C).

These studies

show that MP isolated from normal human plasma similar to those generated in
vitro from cultured EC could bind and activate platelets in a CD36 dependent
manner.
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Figure 12. MP isolated from normal healthy subjects bind and activate
platelets in a CD36 dependent manner. MP were isolated from normal healthy
volunteers and characterized and counted. (A) Flow cytometry histogram
showing that human blood-derived MP stain with a PE-conjugated anti-CD105
IgG (solid line). (B) Flow cytometry histogram showing that platelets did not react
with the anti-CD105 IgG (dotted line) but when incubated with human (CD105
positive) MP at a ratio of 1:9, the platelets acquired PE fluorescence (solid line).
Washed platelets from CD36 expressing donors were incubated with CD105
positive human blood-derived MP (1:9) or buffer control for 30min and then
stimulated with 1μM ADP. They were then incubated with FITC-conjugated
PAC1 and analyzed by flow cytometry. (C) Histogram showing increased PAC-1
binding to CD36-expressing platelets when pre-incubated with human bloodderived MP (solid bold line). Binding was significantly decreased when platelets
were pre-incubated with anti-CD36 IgG (solid thin line). Histograms are
representative of at least three different experiments.
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MP isolated from normal subjects augmented platelet aggregation in a
CD36-dependent manner:
Human plasma derived MP were incubated with PRP from healthy human
volunteers prior to stimulation with 2 µM ADP. Since we observed a subtle
decrement in CD36 null platelet responses to low doses of ADP (Figure 10C),
ADP concentrations were adjusted to produce the same aggregation response
in both the CD36 null and CD36 expressing platelets. As shown in Figure 13
left panel, when human plasma derived MP were incubated with CD36
expressing platelets, there was a significant enhancement in the aggregation
response to ADP. This was not observed when human plasma derived MP
were incubated with CD36 null platelets (Figure 13, right panel). These studies
show that blood-borne MP have similar effects as culture derived EMP on
platelet function.
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Figure 13. MP isolated from normal healthy subjects augment platelet
aggregation in a CD36 dependent manner.
PRP from healthy CD36
expressing (A) or CD36 null (B) human subjects was mixed with MP isolated
from plasma of 13 normal healthy subjects and then stimulated with 1μM ADP
(A) or 2µM ADP (B). Aggregation was assessed turbidometrically as in Figure
10. Tracing is representative of findings from at least 5 different normal subjects.
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CD105 staining in thrombi from CD36 null mice was decreased:
Ongoing studies in the lab by a colleague had shown that the carotid artery
occlusion times in CD36 wild type was significantly longer compared to knock out
mice. We hypothesized that one of the contributing factors to this could be EMPplatelet interaction in CD36 wild type mice.To determine if MP and platelets
interact in vivo, carotid arteries were injured by FeCl3 in wild type and CD36
knock out mice. The thrombosed arteries were sectioned and immunostained
with an endothelial cell specific antibody to CD105 and a platelet specific
antibody to CD61, followed by detection with secondary antibodies conjugated
with different color fluorophores. Nuclei were stained with DAPI. We reasoned
that CD105 staining of thrombi would reflect incorporation of EC-derived MP into
the thrombi. Images (Fig. 14) were acquired by confocal microscope from wild
type (A) and CD36 null mice (B). Each image has four panels showing blue
nuclei (DAPI), red CD105 suggestive of EMP, green platelets (CD61) and a
merged image. When we compared these two images, we observed significantly
more CD105 staining within the thrombi from wild type mice (A) and also more
colocalizing areas between the red EMP and the green platelets (yellow) in the
merge imaged compared to CD36 null mice (B).
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Fig 14: Detection of EMP in thrombi of CD36 wild type and knock out mice.
Immunohistochemistry of cryo preserved carotid artery sections following FeCl3
injury in A) wild type and B) CD36 knock out mice. Section were stained with
DAPI (blue), CD105 (red), platelets (green) and images merged. The merged
section when compared show less CD105 in the CD36 null mice compared to the
wildtype. (C) Quantification of CD105 fluorescenc in thrombi showed a significant
difference (pvalue=0.006)between WT and null mice.
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CHAPTER IV

LEVELS OF CD36 EXPRESSION ON PLATELETS MODULATE PLATELET
FUNCTION

Development of an assay to quantify platelet CD36:
Platelet rich plasma from healthy human volunteers was stained with anti CD36
antibody or its isotype control to quantify CD36 expression levels on platelet
surface. Mean fluorescence intensity was quantified by a standard curve
generated with the PE-Quantibrite Beads (BD Biosciences) using a mixture of
beads tagged with defined amounts of PE ranging from 200 to 70000 molecules
per bead (Fig 15). Knowing the molar ratio of PE to anti-CD36 immunoglobulin
(supplied by the manufacturer) allowed us to calculate the number of bound
antibody molecules on each platelet by comparing mean fluorescence intensity to
the standard curve, and hence, the number of CD36 molecules per platelet. Fig
16 shows typical anti-CD36 fluorescence histograms of platelets from a high (top
panel), low (bottom left) and null (bottom right) donor.
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Fig 15. Quantification of platelet CD36 expression: Flow cytometry of PEQuantibrite beads on forward scatter vs fluorescence intensity (upper left panel)
and histogram (upper right panel) showing four ranges of fluorescent beads and
when plotted against the number of PE molecules per bead as per
manufacturer’s instructions, a graph standard curve (bottom panel) was obtained.
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Fig 16. Detection of CD36 expression in human subjects: Platelet Rich
Plasma (PRP) from human subjects were incubated with either PE-conjugated
CD36 antibody (blue) or its isotype control (red) and then analyzed by flow
cytometry. This helped to identify CD36 expresser (Top panel), CD36 low
expresser (left, bottom panel) and CD36 null donors (right, bottom panel).
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CD36 expression on platelets is variable:
Quantification of the flow cytometry data allowed us to assess the range of CD36
expression in the healthy human population. In a sample size of 32 normal
healthy volunteers, the CD36 expression on platelets ranged from as low as zero
to as high as 14000 molecules per platelet. The mean was 6005±1484, the
median was 5766 per platelet.

14000
12000
10000
8000
6000
4000

Mean
Median

2000
0

Fig 17: CD36 distribution in the population is variable. CD36 expression on
platelets in a small group of healthy human volunteers was quantified as
described above. The range of CD36 expression was as low as 2000/platelet to
as high as 14000/platelet. Also shown are the mean (6005) and median (5766)
values.
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CD36 expression levels on platelets from individual donors were consistent
over time:
Of the 32 normal healthy volunteers tested, a representative group of five
individual donors showed consistent levels of CD36 expression on at least five
repeated analyses. Analyses done over three years at different times in the day
were also consistent (Fig 18).

PE
conjugated

PE
conjugated

PE
conjugated

Isotype

Isotype

Isotype

Donor12 on 8.26.05

Donor12 on 2.12.06

Donor12 on 8.22.07

Fig 18. CD36 expression on platelets were consistent over time. 3
representative histograms from the same subject over three years (2005, 2006
and 2007) at different times of the day. CD36 expression is shown by green and
its isotype control by red.
Table 4: Summary of CD36 analysis in different donors on different days

Table 4 shows the mean, SD and coefficient of variance for each reading for 4
donors on 4 different time points.
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Change of CD36 expression with platelet activation does not show
significant difference among donors:
As reported by others (Kestin et al., 1993; Murasaki et al., 2007; Rinder et al.,
1991), we found that when activated, platelet CD36 levels increases by about
20%. Importantly, there was no significant difference in the % increase in CD36
expression among donors (high expresser and medium expresser), regardless of
resting levels of expression (Fig 19). This suggests that the wide variability in
platelet CD36 expression cannot be accounted by differences in degrees of in
vivo or ex vivo platelet activation among donors.

7

6

5

4

3

2

1

0

high expresser

medium expresser

Fig 19. Difference in platelet CD36 expression between resting and
activated platelets. Platelets from high and medium expresser were stained with
either a PE- conjugated anti CD36 antibody or its isotype control. After activation
by ADP10uM, platelets from high or medium donors (black bars) showed the
same difference in expression when compared to resting (blue bars) platelets.
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CD36 surface expression correlates with total CD36 protein:
Variable CD36 surface expression on platelets could be due to differences in
cellular localization or distribution rather than total expression. To test this,
platelet protein lysates from high, medium and low expessers were subjected to
Western Blot analyses to detect total CD36 protein (Fig 20A). Platelet GPIX or
actin were used as internal controls (Fig 20B). Platelet CD36 was expressed as a
ratio to GPIX and showed considerable variance. We saw a good association
(r2=0.99) between the number of CD36 surface molecules

and the normalized

CD36 protein (Fig 20C) suggesting that the variance in CD36 expression was
due to differences in megakaryocyte CD36 synthesis and not intracellular
distribution.

78

A
CD36
b actin

CD36 normalized to GPIX

B

C

3000
2500

pixels

2000
1500
1000
500
0
1

2

CD36 expression in PEmols

GPIX

10000
8000
6000

r2=0.99

4000
2000
0
0

3

1000

2000

3000

CD36 normalized to GPIX

Fig 20. Platelet CD36 surface expression correlates with total CD36 protein:
Platelet lysates were immunoblotted (A) with an anti CD36 antibody (clone FA6,
Invitrogen). A specific CD36 band was observed at 88kDa in all samples but of
varying band density. The blot was stripped and reprobed with either a polyclonal
antibody to actin or a monoclonal antibody to platelet GPIX to normalize CD36
expression. Plotting the normalized CD36 expression against the flow based
surface expression of the samples (C), suggested a possible association
between the two (r2=0.99).
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Variability in CD36 expression modulates platelet function:
To assess the functional consequences of this variability in CD36 expression we
studied the effect of oxLDL on platelets from donors with high, medium and low
levels of expression (Fig 21B). It is known that oxLDL can activate platelets in a
CD36 dependent manner (Podrez et al., 2007). To assess platelet activation and
aggregation, we incubated PRP or washed platelets with oxLDL. oxLDL induced
a significant increase in the rate and extent of aggregation response (Fig 21A,
left panel). This effect was not observed in null donors (Fig 21A right panel)
demonstrating CD36 dependence.
To determine the effect of oxLDL on platelet activation and secretion, we
assessed platelet P-selectin expression, a marker of α-granule secretion. We
observed that oxLDL could induce a marked increase in the expression of Pselectin

(not

shown).

We

also

found

a

good

correlation

(correlation

coefficient=0.98) between platelet activation by oxLDL and level of CD36
expression (Fig 21C).
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Fig 21. CD36 expression and oxLDL mediated platelet activation. PRP from
healthy CD36 expressing (A, left panel) or CD36 null (A, right panel) donors were
incubated with oxLDL for 30 minutes and then stimulated with ADP 2µM.
Aggregation was assessed turbidometrically with a dual chamber aggregometer.
Tracings show representative aggregometry curves from n=3. (B) Selection of
four normal healthy subjects with their CD36 expression ranging from null to
high. (C) Washed platelets from the selected subjects were incubated with oxLDL
for 30 minutes and the lipid mediated platelet activation was detected by anti Pselectin antibody. Activation data plotted against surface expression of CD36
suggested a good correlation (0.98).
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CHAPTER V

PLATELET CD36 EXPRESSION LEVELS ARE ASSOCIATED WITH GENETIC
POLYMORPHISMS

Platelet CD36 expression is variable: replicability in a larger population:
Using the quantitative immunofluorescence flow cytometric technique to assess
the level of platelet CD36 expression described in Chapter IV, we studied a large
sample size of 567 successive subjects recruited through the Cleveland Clinic
Cardiac Catheterization lab.

As with the normal volunteers, this group also

showed a wide variability in platelet CD36 expression (Fig 22). The mean was
7876±1924 CD36 molecules per platelet and the median was 7611.
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Fig 22: CD36 distribution in a large patient population: The variability of
CD36 expression in a small group of normal healthy population was replicated in
a large (567) patient population. The mean is 7876±1924, median is 7611 CD36
molecules per platelet.
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Patient profile:
Table 5 shows the anthropometric and biochemical data for the study subjects
focusing on those variables that relate to CD36 function. The reference values for
each if the phenotypes were blood cholesterol (CHOL) 200mg/dl; HDL 60mg/dl
(in female) and 50mg/dl (in male); serum triglycerides (TG) 200mg/dl; blood
glucose (GLU) 120mg/dl; platelet count 150,000/ml and Body mass index (BMI)
30. Most patients had a past history of coronary artery disease (CAD) which was
consistent with the fact that they all presented at the Cardiac Catheterization Lab.
Almost 70% patients showed history of smoking in the past and more than 80%
were hypertensive (criteria, 120/90) and more than 50% reported a history of
cardiac disease.
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Table 5: Phenotypic traits of the study subjects. CHOL=cholesterol;
HDL=high density lipopoprotein; LDL=low density lipopoprotein; TG=triglycerides,
GLU=glucose; PLT=platelet count; BMI=body mass index; hx=history of;
CABG=coronary artery by-pass graft surgery; PCI= per cutaneous intervention.
All numbers are total counts and percentages (%).
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SNP analysis:
10 tagged SNPs for CD36 were identified from the HapMap website as described
in the “Materials and Methods” section (Table 2). Table 5 shows the major
findings of our SNP analysis in 567 patients. All the SNPs were in HardyWeinberg equilibrium. When the MFI was considered as a continuous variable,
the none of the SNPs were found to be associated with CD36 expression levels,
although one SNP seemed to have an important effect in females (rs1537593, p
value= 0.019). When the MFI was considered as a binary variant (based on
median values), three SNPs (rs3211864, p value0.023, OR=0.55; rs3211932, p
value=0.02, OR=0.617 and rs1537593, p value=0.03, OR=1.067) were
significantly associated with CD36 expression level. In 2 of 3 SNP analyses,
owing to small number of subjects and the low frequency of the minor allele,
homozygotes or heterozygotes for the rare allele were grouped together. In case
of SNP rs 3211864, the presence of the minor allele (AG or GG) was associated
with lower CD36 expression (OR=0.55). Similarly in case of rs1537593, the minor
allele (TT or CT) was associated with lower CD36 levels. In rs3211932, a
common polymorphism, both the T and the C allele were almost equally
distributed and only the heterozygous (CT) was significantly associated with
levels of CD36.
As Caucasians represent the majority of this population, we reanalyzed the data
excluding the African-American subjects (48 of 567). The same effect was
observed for the SNPs rs3211864 and rs3211932 in the Caucasian population
(519 of 567) (table 6), where the minor alleles were associated with lower levels
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of CD36. One interesting observation in the Caucasians was that one of the
above three SNPs in Table 5 was not significantly associated with the CD36
expression levels (rs 1537593).
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Table 6A: SNP analysis in all patients using MFI as a continuous variable

B: SNP analysis in all patients using MFI as a binary variant (median)

Table 6 SNP analysis in all patients. A) SNP analysis in all subjects using MFI
as a continuous variable. The genotypes are designated as 1, 2 or 3 and are
compared by either ANOVA or T test. A linear correlation coefficient is
designated by r2. For each SNP, the dominant genotype is designated by the
model column. None of the SNPs were associated with CD36 expression levels
in the in the total population. B) SNP analysis using binary va.lues for MFI. The
frequency of each genotype is denoted in percentage (%). P value was corrected
with FDR. Only those with P values < 0.05 and FDR values < 0.2 were reported
as statistically significant findings. When calculating Odds Ratio, owing to smaller
number of subjects, homozygotes for the rare allele (GG in case of SNP
rs3211864) and heterozygotes (AG for rs3211864) were grouped as carriers of
the G allele.

88

Table 7A: SNP analysis in 519 Caucasian patients using MFI as a
continuous variable

7B: SNP analysis in males

89

C: SNP analysis in females

D: SNP analysis in all Caucasians: using MFI as a binary (median) variable

Table 7: SNP analysis in Caucasian patients. A: SNP analysis in all Caucasian
subjects using MFI as a continuous variable. The genotypes are designated as 1,
2 or 3 and are compared by either ANOVA or T test. A linear correlation
coefficient is designated by r2. For each SNP, the dominant genotype is
designated by the model column. None of the SNPs were associated with CD36
expression levels in the in the total (A) or the male (B) Caucasian population.
However, in the female population (C) one SNP rs1537593 was significantly
associated (p=0.018) with CD36 expression levels. (D) When the CD36
expression was divided into two groups their by median values, analysis revealed
two SNPs to be significantly associated with median CD36 expression levels
(3.74); rs3211864 and rs3211932. P value was corrected with FDR. Only those
with P values < 0.05 and FDR values < 0.2 were reported as statistically
significant findings. Odds ratio (OR) for each SNP was calculated with 95%CI.
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Haplotype analysis:
Haplotype analyses in all patients revealed (Table 8) that a number of haplotypes
were associated with CD36 expression. In all instances, the p values were
corrected by TPPFP which is midway between the most conservative bonFerroni and the least conservative False Discovery Rate (FDR) statistic.
Considering TPPFP at a significance level of 0.2, 4 haplotypes were found to be
significantly associated with CD36 expression levels. These are CA, GTGT,
TGTC, and GTGTC. Of these, the most significant haplotype was GTGTC
(3,4,5,6,7), p value= 0.0044, TPPFP= 0.13. G allele of SNP5 (rs3211864)
seemed to have an important effect in the outcome of these haplotypes as seen
with the SNP analysis.
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Table 8: Haplotype analysis of CD36 expression in all patients

Table 8. Haplotypes associated with MFI. showing the haplotypes associated
with CD36 expression. P value, adjusted P value (TPPFP ) and OR (Odd’s ratio)
of the significant base is also shown. GTGTC was the haplotype associated most
significantly with levels of CD36 (p= 0.0044, TPPFP= 0.42). The Odds of this
haplotype of being associated with the CD36 levels was 0.42.
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CHAPTER V

DISCUSSION

Endothelial derived microparticles bind and activate platelets in a CD36
dependent manner
In the present study we demonstrated using inhibitory antibodies, a
competitive ligand (oxLDL), and platelets from CD36 null donors, that EMP
bound to resting platelets in a CD36-dependent manner. Binding was assessed
by both flow cytometry and immunofluorescence microscopy. Our studies using
annexin V or more specifically a monoclonal antibody to PS to mask surface
PS/oxPS suggest that it is PS exposed on EMP surfaces during their formation
that serves as a ligand for platelet CD36. This is consistent with previous studies
from our lab and others that showed that PS and/or oxPS serve as a ligand on
apoptotic cells and shed photoreceptor outer segments facilitating CD36-
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dependent recognition and internalization by phagocytic cells (Greenberg et al.,
2006; Ryeom et al., 1996; Sun et al., 2006). In these previous studies, CD36
was shown to initiate a signal in the phagocyte that resulted in internalization of
the bound particle (Greenberg et al., 2006; Ryeom et al., 1996; Sun et al., 2006).
We and others have also defined CD36-mediated signals in macrophages
that are required for oxLDL uptake and foam cell formation and for clearance of
bacterial products (Stuart et al., 2005).

Since platelets are probably not

phagocytic cells, we hypothesized that CD36 signaling induced by MP might
modulate platelet activation.

To test this hypothesis, we demonstrated using

both turbidometric platelet aggregation studies and flow cytometry assays that
EMP augment platelet aggregation at low doses of the weak agonist ADP (1-4
µM).

This effect was abrogated by CD36 inhibitory antibodies and was not

observed in platelets from CD36 null donors.
The classic platelet activation model suggests that agonists, such as
collagen, thrombin and epinephrine, interact with platelet surface receptors, most
of which are G protein coupled receptors (GPCR), to initiate intracellular
signaling events that lead to activation of integrins, reversible platelet
aggregation, and secretion of platelet granule contents.

“Outside-in” signals

mediated by integrin α2bβ3 and additional GPCR activation via secretion of ADP
and thromboxane result in enhancement of the signal and ultimately stable
platelet aggregation and thrombus formation. Recent studies have significantly
advanced and refined this model.

A large number of signaling molecules

(receptors and ligands) have been identified that appear to act within the platelet-
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platelet contact zone after the aggregation event. These include ephrins and
their receptors, eph kinases (Prevost et al., 2005; Prevost et al., 2004), gas6
(Angelillo-Scherrer et al., 2005; Angelillo-Scherrer et al., 2001), and its tyrosine
kinase receptors, mer, tyro3, and axl, PECAM-1 (Falati et al., 2006), CD40 and
CD40L (Henn et al., 1998; Hermann et al., 2001) and semaphorin 4D (Zhu et al.,
2007). It has been suggested that after aggregation, platelets form a “synapse”
(Brass et al., 2006) facilitating signaling by membrane tethered receptor/ligand
pairs and localizing secreted and shed ligands.

This promotes growth and

stability of the thrombus (Jackson, 2007).
Our studies suggest that CD36 can also function as a signaling receptor on
platelets capable of modulating platelet activation and aggregation. Unlike the
case of most of the receptor-ligand pairs described above, CD36 may function on
resting platelets to signal and sensitize platelets to activation by other agonists.
Importantly, the ligands that we have shown to bind CD36 on platelets (oxidized
lipids and EMP) are generated as a consequence of diseases known to be
associated with increased thrombotic risk. We thus propose a model whereby
CD36 ligands presented to platelets renders them “hyperreactive”, predisposing
patients to pathological thrombosis. In support of this model, we demonstrated
that both EMP isolated from HUVEC culture and MP isolated from the blood of
healthy human subjects augmented platelet aggregation in a CD36-dependent
manner. In times of pathological stress, the number of circulating MP presenting
to platelets increases, leading to binding and activation and this might account, at
least in part, for the higher risk of thrombosis in these stressful conditions. Our
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model does not preclude a role for CD36 in the platelet synapse. It is also
possible that ligands such as EMP that are generated during an acute thrombotic
event could interact with CD36 in the platelet contact zone to increase responses
to other signals and thereby provide a positive feedback loop during normal
hemostasis.

Fig 23. Model showing platelet CD36-MP interaction. EMP bind platelet CD6
and in turn can activate platelets, thus leading to recruitment of more platelets in
a thrombi of CD36 expressing platelets(right panel) forming a feed forward loop
promoting thrombus formation; whereas in the CD36 null platelets, this loop is
absent

96

In fact our data supports this; ADP dose response in CD36 null donors
was blunted compared with CD36 expressing donors. The mechanism of this
effect is unclear but our in-vivo study showed decreased EMP (CD105) staining
in the thrombi from CD36 null mice suggesting that MP generated during normal
hemostasis might serve as a ligand to facilitate platelet activation. Thus CD36
could potentially modulate platelet function in both resting state as well as after
platelet activation in the platelet synapse.
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Levels of CD36 expression on platelets modulate platelet function

In the first part of our studies we established the hypothesis that CD36ligand interactions could “prime” or sensitize platelets to activation by low doses
of agonists. We had seen that the absence of CD36 could significantly alter
platelet function. We thus hypothesized that levels of CD36 expression in healthy
individuals could modulate platelet function.
We reported here using a quantitative flow cytometric method that CD36
expression on resting platelets among individual donors is highly variable with
expressions ranging from 200 to 14000 molecules/ platelet. A recent study in this
lab, in collaboration with others, has characterized the role of oxLDL as a ligand
for platelet CD36 and shown that oxLDL can mediate platelet activation (Podrez
et al., 2007). We showed here by flow cytometry and platelet aggregation studies
that oxLDL could modulate platelet function in a CD36 dependent manner.
When we selected four donors who were high, middle or low expressers
and assessed platelet activation after pre-incubation with oxLDL, we observed
that the extent of oxLDL induced platelet activation correlated closely with CD36
levels on the platelets (r2=0.98) (Fig 21). These data suggest that individuals with
high expression of CD36 on platelets might be more susceptible to platelet
activation and, in turn, more prone to acute thrombotic events, while those with
low levels of expression might have lower risk.
The mechanisms responsible for variability of platelet CD36 expression
are not known. We propose here that a component of the variability might be
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genetic, but it is also likely that non-genetic e.g. environmental factors contribute.
CD36 expression in monocytes and macrophages has been shown to be
regulated by a number of conditions and agents. For example, in monocytes and
macrophages PPARγ agonists, statins, vitamin E, HIV protease inhibitors, diet
(fat), hyperglycemia, oxLDL, cytokines (IL4, TGFb, M-CSF) have been shown to
influence CD36 expression (Feingold et al., 2004; Feng et al., 2000; Han et al.,
2000; Han et al., 1999; Huh et al., 1995; Huh et al., 1996; Kwok et al., 2007;
Tontonoz et al., 1998), but it is not known whether any of these agents could
affect platelet CD36 expression at the megakaryocytic level.
CD36 (GPIV) expression on platelets has also seen to vary in certain
disease conditions. For example, Rinder et al had showed that cardiopulmonary
bypass produced significant increase in platelet Glycoprotein IV expression after
2-4 hours of the bypass (Rinder et al., 1991). Changes in platelet surface CD36
expression were also observed by Kestin et al who reported an increase in
expression of GPIV detected by the monoclonal antibody OKM5 in a group of
sedentary subjects after strenuous exercise (Kestin et al., 1993). In another
report, CD36 expression detected by two antibodies, OKM5 and GS95 in
subjects who underwent coronary stenting surgery reflected the level of platelet
mediated restenosis (Murasaki et al., 2007). In all of these studies increase in
CD36 expression was associated with evidence of platelet activation. This is
consistent with our study where we showed that platelet CD36 expression
increased by 20% after activation.
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Platelet CD36 expression levels are associated with genetic
polymorphisms

CD36 is a highly polymorphic gene, yet systematic studies related to its
genetic polymorphisms and their functional consequences are limited. In one of
the few studies reported, 5 polymorphisms in Caucasians were used to define
two specific LD blocks in the CD36 gene and thereby classify the population into
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several haplotypes (Ma et al., 2004). There was a correlation between one of
these haplotypes and circulating free fatty acid levels. Since CD36 is a fatty acid
transporter, the results suggested an association with CD36 expression on fat
and/or muscle, but there was no experimental evidence to support this.
Generally, a haplotype is a collection of SNPs that are inherited together.
This coinheritance suggests that some of these SNPs may be strongly linked to
each other; this is known as linkage disequilibrium (LD). This strong association
also implies that analysis of any one of these SNPs within a region of LD would
provide us information on all the other SNPs in that region. These “informative”
SNPs are known as Tagged SNPs (Project, 2003). In our study, we identified 10
regions of LD based on data available through the Human Genome project and
then chose 10 tagged SNPs for analysis from each region based on the criterion
of at least 5% frequency of the minor allele.
We then used these ten tagged SNPs to genotype 567 unrelated subjects
who presented to the Cleveland Clinic Cardiac Catheterization lab for
cardiovascular complaints. SNP analysis revealed that 3 SNPs were significantly
associated with CD36 levels. Interestingly, both the minor alleles of these 3
SNPs were associated with low CD36 expression.
Polymorphisms can affect the protein expression levels by several
mechanisms. An unstable protein can result if the polymorphism is within the
coding region of the gene. These mutant proteins are often mistargeted and
degraded, for example, CD36 null mutation C478T. Such polymorphisms could
result in single amino acid changes or could cause a frame shift, generating a
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missense and /or translation stop codon and reduce transcripts (as seen in some
CD36 null mutations). Polymorphisms can also occur in non-coding exons that
can affect the mRNA stability or mRNA translational efficacy. SNPs located at the
intron-exon splice site could alter protein structure or expression by altering
splicing. SNPs in the gene promoter/ enhancer regions could affect transcription
factor binding and thus influence mRNA transcription. Recently, mutations/
polymorphisms in regulatory micro RNA binding sites have been described and
related to transcriptional activity.
SNPs can be either synonymous (silent) or non-synonymous (a change in
the protein). While non-synonymous SNPs are associated with most single gene
diseases, most SNPs are non-coding and most SNPs identified in genetic
association studies of complex multigenic diseases are non-coding. Most CD36
SNPs identified to date are in the non-coding region. In our study, all 10 tag
SNPs were non-coding. They were mostly intronic, although one of them was in
the 5’ untranslated region of the mRNA coding region (rs9918586). All the 3
SNPs significantly associated with low CD36 expression levels in our study were
intronic. Although we have shown an association between these 3 SNPs and
CD36 levels, it does not imply that these SNPs are responsible for reduced CD36
protein expression. These tag SNPs probably predict the presence of other SNPs
which are in LD and these are equally or more likely to be responsible for the
change in CD36 protein expression.
There have been several studies in the past on polymorphisms of platelet
receptors and their functional impact. The most clinically relevant platelet
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polymorphisms involve surface glycoprotein molecules that play a key role in
platelet adhesion, activation and aggregation. These include, α3a, α2b, GPIbα,
GPIbβ and integrin α2. For example the PlA2 polymorphism (leu/pro 33,
1565T/C), first shown by Kunicki and Aster (Kunicki and Aster, 1978) is a T→C
substitution at position1565 in Exon 2 of α2bβ3 gene (Newman et al., 1989).
There is conflicting evidence, however about whether this mutation could affect
platelet function. The same group also identified a Sra polymorphism in α3a
(Arg636→cys) (Santoso et al., 1994) but this was not associated with any change
in platelet expression of α2bβ3 on the platelet nor with any platelet adhesive
function. Afshar-Kharghan identified a Kozak-sequence polymorphism in GP1bα
(-5C→T) where the -5C allele is associated with increased surface expression of
GP1bα on platelets or cell lines expressing these mutants (Afshar-Kharghan et
al., 1999). Kozak sequence consensus states that translation is most efficient
with C at -5 position of the start codon ATG (Kozak, 1984) In the same lines, the
Bra polymorphism (Br 1648G→A) was associated with lower platelet expression
levels of integrin α2β1 (Kunicki et al., 1997), and in the -807C→T polymorphism,
the T allele was associated with higher levels of α2β1 (Corral et al., 1999a; Corral
et al., 1999b).
The present study structure does not give us enough information about
CD36 inheritance in general. This draws our attention to the fact that the
population under discussion is a mixed population in terms of health and disease
including hypertension, obesity, smoking and atherosclerosis. Also, there has
been considerable evidence that hydroxylmethyl-glutaryl CoA inhibitors or statins
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can actually reduce the platelet surface expression of CD36 and thus reduce
platelet reactivity to oxLDL, thereby contributing towards anti-thrombotic risk
(Bruni et al., 2005; Puccetti et al., 2002; Puccetti et al., 2003; Puccetti et al.,
2005). Our sample group is heterogenous, some of patients may or may not
have been on statins, and this may mask some of the genetic effects. We
therefore need to repeat the study in a large normal healthy population who are
not on any medication and without any risk factors for atherosclerotic diseases to
address this issue.
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APPENDIX
Association of CD36 tagged SNPs with other phenotypes:
Although not included in the initial proposal, accessibility to other phenotypic data
(Table 4, Chapter V) for the patient population through Gene Bank allowed us to
do association analyses between these phenotypes and CD36 genotypes. Pilot
studies revealed that CD36 SNPs were associated with BMI (body mass index).
Considering all patients, G allele in the SNP rs3211864 was significantly
associated with lower BMI (body mass index) (P value= 0.001). Interestingly, the
minor allele of the same SNP was also associated with lower levels of CD36
expression (Chapter IV). Similar results were obtained with analysis of the data in
Caucasian patients (data not shown). Haplotype analyses also revealed an
association of CD36 with BMI (Table 2). This association is probably relevant
because our group in collaboration with others have shown that body weight of
CD36 null male (less so in female) mice were lower than their age matched wild
type controls (Goudriaan et al., 2002). We also showed that the daily food intake
was also lower in CD36 null mice compared to the wild types. Interestingly,
Laugerette et al demonstrated that CD36 was present at the apex of taste buds
and acted as “oral sensor” of fat. CD36 null mice were less attracted by fatty diet
(Laugerette et al., 2005) suggesting that this could contribute towards less body
weight and BMI. Recently, a study of 219 Korean patients with severe coronary
artery disease revealed that homozygosity of the polymorphism (TG repeat in
intron 3) was significantly associated with higher BMI in men compared to control
male subjects (Min Yun et al., 2007). We show here that CD36 SNPs could
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associate with BMI, however further analysis with a large number of normal
control subjects is required to conclude anything definitive.

Table 1: SNP analysis for BMI in all patients

Table 1: SNPs associated with BMI. Two SNPs were significantly associated
with BMI. The p value is supplemented with (FDR). Odds Ratio with 95%CI for
each SNP was calculated.
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Table 2: Haplotype analysis in all patients: BMI

Table 2: Haplotypes associated with BMI. Haplotype analysis revealed several
haplotypes to be associated with BMI. P value and TPPFP for each haplotype
combination are shown. OR with 95% CI are also shown.
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